QuidelOrtho 10-K 16 Feb 17 2016 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2016	Feb. 10, 2017	Jun. 30, 2016
Document And Entity Information [Abstract]
Entity Registrant Name	QUIDEL CORP /DE/
Entity Central Index Key	353,569
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Document Type	10-K
Document Period End Date	Dec. 31, 2016
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	FY
Trading Symbol	QDEL
Amendment Flag	false
Entity Common Stock, Shares Outstanding		32,950,618
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Public Float			$ 486,300,707

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Current assets:
Cash and cash equivalents	$ 169,508	$ 191,471
Accounts receivable, net	24,990	18,398
Inventories	26,045	26,388
Restricted cash	0	63
Prepaid expenses and other current assets	4,851	4,344
Total current assets	225,394	240,664
Property, plant and equipment, net	50,858	52,547
Goodwill	83,834	80,730
Intangible assets, net	27,639	31,833
Other non-current assets	525	731
Total assets	388,250	406,505
Current liabilities:
Accounts payable	16,047	8,675
Accrued payroll and related expenses	9,642	9,627
Current portion of lease obligation	98	585
Current portion of contingent consideration	2,826	1,286
Deferred grant revenue	0	3,658
Other current liabilities	4,999	6,999
Total current liabilities	33,612	30,830
Long-term debt	144,340	143,297
Lease obligation, net of current portion	3,979	4,032
Contingent consideration—non-current	2,349	4,230
Deferred tax liability—non-current	58	1,970
Income taxes payable	1,045	910
Deferred rent	1,965	2,296
Other non-current liabilities	272	264
Commitments and contingencies (Note 6)
Stockholders’ equity:
Preferred stock, $.001 par value per share; 5,000 shares authorized; none issued or outstanding at December 31, 2016 and 2015	0	0
Common stock, $.001 par value per share; 97,500 shares authorized; 32,897 and 33,323 shares issued and outstanding at December 31, 2016 and 2015, respectively	33	33
Additional paid-in capital	204,905	209,121
Accumulated other comprehensive loss	(53)	(31)
(Accumulated deficit) retained earnings	(4,255)	9,553
Total stockholders’ equity	200,630	218,676
Total liabilities and stockholders’ equity	$ 388,250	$ 406,505

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2015	Dec. 31, 2014
Statement of Financial Position [Abstract]
Preferred stock, par value per share	$ 0.001	$ 0.001
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value per share	$ 0.001	$ 0.001
Common stock, shares authorized	97,500,000	50,000,000
Common stock, shares issued	32,897,000	33,323,000
Common stock, shares outstanding	32,897,000	33,323,000

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Income Statement [Abstract]
Total revenues	$ 191,603	$ 196,129	$ 184,158
Costs and expenses
Cost of sales (excludes amortization of intangible assets of $6,485, $6,341, and $6,283, respectively)	73,414	71,688	74,180
Research and development	38,672	35,514	37,913
Sales and marketing	47,821	47,886	43,076
General and administrative	27,062	29,447	25,811
Amortization of intangible assets from acquired businesses and technology	9,073	8,856	8,828
Impairment loss	0	0	3,558
Total costs and expenses	196,042	193,391	193,366
Operating (loss) income	(4,439)	2,738	(9,208)
Interest expense, net	(11,760)	(12,035)	(1,775)
Loss before benefit for income taxes	(16,199)	(9,297)	(10,983)
Benefit for income taxes	(2,391)	(3,218)	(3,909)
Net loss	$ (13,808)	$ (6,079)	$ (7,074)
Basic and diluted loss per share	$ (0.42)	$ (0.18)	$ (0.21)
Shares used in basic and diluted per share calculation	32,708	34,104	34,451

Consolidated Statements of Ope5

Consolidated Statements of Operations (Parenthetical) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Income Statement [Abstract]
Amortization of intangible assets	$ 6,485	$ 6,341	$ 6,283

Consolidated Statements of Comp

Consolidated Statements of Comprehensive (Loss) Income - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Statement of Comprehensive Income [Abstract]
Net loss	$ (13,808)	$ (6,079)	$ (7,074)
Other comprehensive loss, net of tax
Changes in cumulative translation adjustment	(22)	(2)	(47)
Comprehensive loss	$ (13,830)	$ (6,081)	$ (7,121)

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity - USD ($) shares in Thousands, $ in Thousands	Total	Common Stock [Member]	Additional paid-in capital [Member]	Accumulated other comprehensive income (loss) [Member]	Retained earnings [Member]
Beginning Balance at Dec. 31, 2013	$ 223,779	$ 34	$ 201,021	$ 18	$ 22,706
Beginning Balance, shares at Dec. 31, 2013		34,073
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock under equity compensation plans	5,471	$ 0	5,471	0
Issuance of common stock under equity compensation plans, shares		428
Issuance of common stock under equity compensation plans	29,758		29,758	0	0
Tax impact from the issuance of convertible senior notes	(11,362)		(11,362)
Tax impact from the issuance of convertible senior notes	6,442		6,442
Stock-based compensation expense	(1,956)		(1,956)
Repurchase of common stock, shares		(68)
Repurchases of common stock	(47)			(47)
Net loss	(7,074)				(7,074)
Ending Balance at Dec. 31, 2014	245,011	$ 34	229,374	(29)	15,632
Ending Balance, shares at Dec. 31, 2014		34,433
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock under equity compensation plans	3,318	$ 0	3,318
Issuance of common stock under equity compensation plans, shares		308
Tax impact from the issuance of convertible senior notes	6,791		6,791
Convertible senior notes, equity portion, net of tax and issuance costs	571		571
Stock-based compensation expense	(30,934)	$ 1	(30,933)
Repurchase of common stock, shares		(1,418)
Repurchases of common stock	(2)			(2)
Net loss	(6,079)				(6,079)
Ending Balance at Dec. 31, 2015	218,676	$ 33	209,121	(31)	9,553
Ending Balance, shares at Dec. 31, 2015		33,323
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock under equity compensation plans	9,365		9,365
Issuance of common stock under equity compensation plans, shares		755
Tax impact from the issuance of convertible senior notes	7,134		7,134
Stock-based compensation expense	(20,168)	$ 0	(20,168)
Repurchase of Convertible Senior Notes	(547)
Repurchase of common stock, shares		(1,181)
Repurchases of common stock	(22)			(22)
Net loss	(13,808)				(13,808)
Ending Balance at Dec. 31, 2016	$ 200,630	$ 33	$ 204,905	$ (53)	$ (4,255)
Ending Balance, shares at Dec. 31, 2016		32,897

Consolidated Statements of Cash

Consolidated Statements of Cash Flows $ in Thousands	12 Months Ended
	Dec. 31, 2016USD ($)	Dec. 31, 2015USD ($)	Dec. 31, 2014USD ($)
OPERATING ACTIVITIES
Net loss	$ (13,808)	$ (6,079)	$ (7,074)
Adjustments to reconcile net loss to net cash provided by operating activities:
Depreciation, amortization and other	22,796	23,386	28,365
Stock-based compensation expense	7,986	7,419	6,724
Impairment loss	0	0	3,558
Amortization of debt discount and deferred issuance costs	5,891	5,664	629
Change in fair value of acquisition contingencies	(485)	(88)	(910)
Change in fair value of acquisition contingencies	(2,603)	(4,027)	(2,744)
Gain on extinguishment of Convertible Senior Notes	(421)	0	0
Excess tax benefit from share-based compensation	0	(571)	0
Excess tax benefit from share-based compensation
Accounts receivable	(6,265)	16,060	(4,547)
Inventories	859	(1,637)	2,862
Prepaid expenses and other current and non-current assets	(552)	(1,039)	787
Restricted cash	63	3,064	(2,158)
Accounts payable	4,323	(3,082)	4,380
Accrued payroll and related expenses	(375)	1,061	1,247
Income taxes payable	48	(64)	(1,036)
Deferred grant revenue	(3,658)	(2,672)	4,301
Other current and non-current liabilities	(1,984)	(1,086)	1,302
Net cash provided by operating activities	11,815	36,309	35,686
INVESTING ACTIVITIES
Acquisitions of property, equipment and intangibles	(11,909)	(17,032)	(11,241)
Acquisition of Immutopics, net of cash acquired	(5,061)	0	0
Net cash used for investing activities	(16,970)	(17,032)	(11,241)
FINANCING ACTIVITIES
Proceeds from issuance of Convertible Senior Notes	0	0	172,500
Proceeds from issuance of common stock	8,575	2,911	4,781
Payments of debt issuance costs	0	(365)	(4,712)
Excess tax benefit from share-based compensation	0	571	0
Payments on lease obligation	(540)	(509)	(441)
Repurchases of common stock	(20,168)	(30,934)	(1,956)
Repayments of Convertible Debt	(4,459)	0	0
Payments on acquisition contingencies	(207)	(129)	(2,112)
Payment for acquisition holdback	0	(229)	0
Net cash (used for) provided by financing activities	(16,799)	(28,684)	168,060
Effect of exchange rate changes on cash	(9)	(17)	2
Net (decrease) increase in cash and cash equivalents	(21,963)	(9,424)	192,507
Cash and cash equivalents, beginning of period	191,471	200,895	8,388
Cash and cash equivalents, at end of period	169,508	191,471	200,895
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION
Cash paid during the period for interest	6,488	6,998	981
Cash paid during the period for income taxes	490	1,922	327
NON-CASH INVESTING ACTIVITIES
Purchase of property, equipment and intangibles by incurring current liabilities	3,280	239	900
NON-CASH FINANCING ACTIVITIES
Decrease of accrued payroll and related expenses upon issuance of common stock	539	408	663
Receivable for stock option exercises	251	0	0
Debt issuance costs by incurring current liabilities	$ 0	$ 0	$ 365

Company Operations and Summary

Company Operations and Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2016
Accounting Policies [Abstract]
Company Operations and Summary of Significant Accounting Policies	Company Operations and Summary of Significant Accounting Policies Quidel Corporation (the “Company”) commenced operations in 1979. The Company operates in one business segment, which develops, manufactures and markets rapid diagnostic testing solutions. These diagnostic tests can be categorized in the following areas: immunoassay, molecular, virology and specialty products. The Company sells its products directly to end users and distributors, in each case, for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, leading universities, retail clinics and wellness screening centers. The Company markets its products in the U.S. through a network of national and regional distributors, and a direct sales force. Internationally, the Company sells and markets through distributor arrangements. The accompanying consolidated financial statements of the Company and its subsidiaries have been prepared in accordance with generally accepted accounting principles in the U.S. Consolidation— The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated. Cash and Cash Equivalents— The Company considers cash equivalents to be highly liquid investments with a maturity at the date of purchase of three months or less. The Company invests its cash equivalents primarily in money market funds and commercial paper. Cash equivalents are maintained with high quality institutions. Accounts Receivable— The Company sells its products directly to hospitals and reference laboratories in the U.S. as well as to distributors in the U.S. and internationally (see Note 7). The Company periodically assesses the financial strength of these customers and establishes reserves for anticipated losses when necessary, which historically have not been material. The Company’s reserves primarily consist of amounts related to cash discounts and contract rebates. The balance of accounts receivable is net of reserves of $7.2 million and $7.5 million at December 31, 2016 and 2015 , respectively. Concentration of Credit Risk— Financial instruments that potentially subject the Company to significant concentrations of credit risk consists principally of trade accounts receivable. The Company performs credit evaluations of its customers’ financial condition and limits the amount of credit extended when deemed necessary, but generally requires no collateral. Credit quality is monitored regularly by reviewing credit history. The Company believes that the concentration of credit risk in its trade accounts receivables is moderated by its credit evaluation process, relatively short collection terms, the high level of credit worthiness of its customers, and letters of credit issued on the Company’s behalf. Potential credit losses are limited to the gross value of accounts receivable. Inventories— Inventories are stated at the lower of cost (first-in, first-out) or net realizable value. The Company reviews the components of its inventory on a quarterly basis for excess, obsolete and impaired inventory and makes appropriate dispositions as obsolete stock is identified. Inventories consisted of the following, net of reserves of $0.7 million at December 31, 2016 and 2015 (in thousands): December 31, 2016 2015 Raw materials $ 9,297 $ 10,289 Work-in-process (materials, labor and overhead) 7,990 7,441 Finished goods (materials, labor and overhead) 8,758 8,658 Total inventories $ 26,045 $ 26,388 Property, Plant and Equipment— Property, plant and equipment is recorded at cost and depreciated over the estimated useful lives of the assets ( three to 15 years) using the straight-line method. Amortization of leasehold improvements is computed on the straight-line method over the estimated useful lives of the assets. The total expense for depreciation of fixed assets and amortization of leasehold improvements was $13.4 million , $12.7 million and $10.3 million for the years ended December 31, 2016 , 2015 and 2014 , respectively. Maintenance and minor repairs are charged to operations as incurred. Property, plant and equipment consisted of the following (in thousands): December 31, 2016 2015 Equipment, furniture and fixtures $ 61,972 $ 59,736 Building and improvements 34,243 33,048 Leased instruments 24,014 18,280 Land 1,080 1,080 Total property, plant and equipment, gross 121,309 112,144 Less: accumulated depreciation and amortization (70,451 ) (59,597 ) Total property, plant and equipment, net $ 50,858 $ 52,547 Goodwill and Intangible Assets— Intangible assets are recorded at cost and amortized on a straight-line basis over their estimated useful lives, except for software development costs and indefinite-lived intangibles such as goodwill. Software development costs associated with software to be sold, leased or otherwise marketed are expensed as incurred until technological feasibility has been established. After technological feasibility is established, software development costs are capitalized. The capitalized cost is amortized on a straight-line basis over the estimated product life or on the ratio of current revenues to total projected product revenues, whichever is greater. Amortization expense related to the capitalized software costs was $0.5 million , $0.6 million and $0.6 million for the years ended December 31, 2016 , 2015 and 2014 , respectively. The Company had goodwill of $83.8 million as of December 31, 2016 and $80.7 million as of December 31, 2015 . Intangible assets consisted of the following (dollar amounts in thousands): December 31, 2016 December 31, 2015 Description Weighted-average useful life (years) Gross assets Accumulated amortization Net Gross assets Accumulated amortization Net Purchased technology 8.4 53,600 (41,369 ) 12,231 52,560 (34,911 ) 17,649 Customer relationships 7.6 7,157 (5,928 ) 1,229 7,171 (4,972 ) 2,199 License agreements 10.4 6,009 (3,222 ) 2,787 5,512 (2,542 ) 2,970 Patent and trademark costs 12.0 11,240 (3,522 ) 7,718 10,530 (2,588 ) 7,942 Software development costs 5 6,000 (2,326 ) 3,674 2,913 (1,840 ) 1,073 Total intangible assets $ 84,006 $ (56,367 ) $ 27,639 $ 78,686 $ (46,853 ) $ 31,833 Amortization expense was $9.5 million , $10.2 million and $17.4 million for the years ended December 31, 2016 , 2015 and 2014 , respectively. Included in this amortization expense amount for 2015 and 2014 is $0.7 million , and $8.0 million , respectively, of amortization for licensed technology recorded in cost of sales. This amount is related to the purchase of a license pursuant to the Alere Amendment as discussed in Note 6. The intangible asset associated with this intangible was fully amortized in the first quarter of 2015. The expected future annual amortization expense of the Company’s intangible assets is as follows (in thousands): For the years ending December 31, Amortization expense 2017 $ 9,822 2018 4,332 2019 3,079 2020 2,700 2021 2,582 Thereafter 5,124 Total $ 27,639 The Company recorded a $1.6 million impairment loss related to a discontinued research and development named Project Stella (Bobcat) during the third quarter of 2014. See further discussion in Note 10. The Company completed its annual evaluation for impairment of goodwill and determined that no impairment of goodwill existed as of December 31, 2016 . Impairment of Long-Lived Assets— The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the total book value of an asset may not be recoverable. An impairment loss is recognized when estimated undiscounted future cash flows expected to result from the use of the asset and the eventual disposition are less than its carrying amount. An impairment loss is equal to the excess of the book value of an asset over its determined fair value. For the year ended December 31, 2014, the Company recorded a $1.5 million impairment loss on software development costs related to Project Stella. See further discussion in Note 10. The Company recorded no impairment losses for the years ended December 31, 2016 and 2015. Other current liabilities— Other current liabilities consisted of the following (in thousands): December 31, 2016 2015 Customer incentives $ 3,766 $ 4,030 Accrued interest 227 202 Other 1,006 2,767 Total other current liabilities $ 4,999 $ 6,999 Convertible Debt— The Company accounts for convertible debt instruments that may be settled in cash upon conversion (including combination settlement of cash equal to the “principal portion” and delivery of the “share amount” in excess of the conversion value over the principal portion in shares of common stock and/or cash) by separating the liability and equity components of the instruments in a manner that reflects our nonconvertible debt borrowing rate. The Company determines the carrying amount of the liability component by measuring the fair value of similar debt instruments that do not have the conversion feature. If no similar debt instrument exists, the Company estimates fair value by using assumptions that market participants would use in pricing a debt instrument, including market interest rates, credit standing, yield curves and volatilities. Determining the fair value of the debt component requires the use of accounting estimates and assumptions. These estimates and assumptions are judgmental in nature and could have a significant impact on the determination of the debt component, and the associated non-cash interest expense. See Note 2 for additional discussion of the Convertible Senior Notes issued in December 2014. Revenue Recognition— The Company records revenues primarily from product sales. These revenues are recorded net of rebates and other discounts that are estimated at the time of sale, and are largely driven by various customer program offerings, including special pricing agreements, promotions and other volume-based incentives. Revenue from product sales are recorded upon passage of title and risk of loss to the customer. Passage of title to the product and recognition of revenue occurs upon delivery to the customer when sales terms are free on board (“FOB”) destination and at the time of shipment when the sales terms are FOB shipping point and there is no right of return. A portion of product sales includes revenues for diagnostic kits, which are utilized on leased instrument systems under the Company’s “reagent rental” program. The reagent rental program provides customers the right to use the instruments at no separate cost to the customer in consideration for a multi-year agreement to purchase annual minimum amounts of consumables (“reagents” or “diagnostic kits”). When an instrument is placed with a customer under a reagent rental agreement, the Company retains title to the equipment and it remains capitalized on the Company’s Consolidated Balance Sheets as property and equipment. The instrument is depreciated on a straight-line basis over the life of the instrument. Depreciation expense is recorded in cost of sales included in the Consolidated Statements of Operations. The reagent rental agreements represent one unit of accounting as the instrument and consumables (reagents) are interdependent in producing a diagnostic result and neither has a stand-alone value with respect to these agreements. No revenue is recognized at the time of instrument placement. All revenue is recognized when the title and risk of loss for the diagnostic kits have passed to the customer. Royalty income from the grant of license rights is recognized during the period in which the revenue is earned and the amount is determinable from the licensee. The Company earns income from grants for research and commercialization activities. On November 6, 2012, the Company was awarded a milestone-based grant totaling up to $8.3 million from the Bill and Melinda Gates Foundation to develop, manufacture and validate a quantitative, low-cost, nucleic acid assay for HIV drug treatment monitoring on the integrated Savanna MDx platform for use in limited resource settings. Upon execution of the grant agreement, the Company received $2.6 million to fund subsequent research and development activities and received milestone payments totaling $2.5 million in 2013. On September 10, 2014, the Company entered into an amended grant agreement with the Bill and Melinda Gates Foundation for additional funding of up to $12.6 million in order to accelerate the development of the Savanna MDx platform in the developing world. Upon execution of the amended grant agreement, the Company received $10.6 million in cash. The Company received payments of $2.4 million in April 2015 and $2.8 million in July 2016 based on milestone achievements for both the original and the amended grant agreements. Under the original and amended grant agreements, the Company recognized grant revenue on the basis of the lesser of the amount recognized on a proportional performance basis or the amount of cash payments that were non-refundable as of the end of each reporting period. For the years ended December 31, 2016 , 2015 and 2014 , the Company recognized $6.5 million , $5.1 million and $6.3 million as grant revenue, respectively. Cash payments received were restricted as to use until expenditures contemplated in the grant were incurred or committed. As of December 31, 2016 , all payment related milestones have been achieved and all of the grant revenue of $20.9 million has been recorded. Research and Development Costs— Research and development costs are charged to operations as incurred. In conjunction with certain third party service agreements, the Company is required to make periodic payments based on achievement of certain milestones. The costs related to these research and development services are also charged to operations as incurred. Product Shipment Costs— Product shipment costs are included in sales and marketing expense in the accompanying Consolidated Statements of Operations. Shipping and handling costs were $3.8 million , $3.9 million and $3.8 million for the years ended December 31, 2016 , 2015 and 2014 , respectively. Advertising Costs— Advertising costs are expensed as incurred. Advertising costs were $0.3 million , $0.7 million and $0.4 million for the years ended December 31, 2016 , 2015 and 2014 , respectively. Deferred Rent— Rent expense is recorded on a straight-line basis over the term of the lease. The difference between rent expense and amounts paid under the lease agreement are recorded as deferred rent. Income Taxes— Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes, using enacted tax rates in effect for the year in which the differences are expected to reverse. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized. The Company’s policy is to recognize the interest expense and penalties related to income tax matters as a component of income tax expense. Fair Value of Financial Instruments — The Company uses the fair value hierarchy established in ASC Topic 820 , Fair Value Measurements and Disclosures, that requires the valuation of assets and liabilities subject to fair value measurements using a three tiered approach and fair value measurement be classified and disclosed by the Company in one of the following three categories: Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities; Level 2: Quoted prices for similar assets and liabilities in active markets, quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e. supported by little or no market activity). The carrying amounts of the Company’s financial instruments, including cash, receivables, accounts payable and accrued liabilities approximate their fair values due to their short-term nature. Product Warranty —The Company generally sells products with a limited product warranty and certain limited indemnifications. Due to product testing, the short time between product shipment and the detection and correction of product failures and a low historical rate of payments on indemnification claims, the historical activity and the related expense were not significant for the fiscal years presented. Stock-Based Compensation —Compensation expense related to stock options granted is recognized ratably over the service vesting period for the entire option. The total number of stock options expected to vest is adjusted by estimated forfeiture rates. The Company determined the estimated fair value of each stock option on the date of grant using the Black-Scholes option valuation model. Compensation expense for restricted stock units (RSUs) is measured at the grant date and recognized ratably over the vesting period. The fair value of RSUs is determined based on the closing market price of the Company’s common stock on the grant date. Computation of (Loss) Earnings Per Share —For the years ended December 31, 2016 , 2015 and 2014 , basic loss per share was computed by dividing net loss by the weighted-average number of common shares outstanding, including restricted stock units vested during the period. Diluted earnings per share (“EPS”) reflects the potential dilution that could occur if the earnings were divided by the weighted-average number of common shares and potentially dilutive common shares from outstanding stock options as well as unvested restricted stock units. Potential dilutive common shares were calculated using the treasury stock method and represent incremental shares issuable upon exercise of the Company’s outstanding stock options and unvested restricted stock units. For the years ended December 31, 2016 , 2015 and 2014 , there were no differences between the number of common shares used for the basic and diluted EPS computation because the Company incurred a net loss and the effect would be anti-dilutive. Stock options and shares of restricted stock that would have been included in the diluted EPS calculation if the Company had earnings amounted to 0.8 million , 1.0 million and 1.1 million for the years ended December 31, 2016 , 2015 and 2014 , respectively. Additionally, stock options are excluded from the calculation of diluted EPS when the combined exercise price, unrecognized stock-based compensation and expected tax benefits upon exercise are greater than the average market price for the Company’s common stock because their effect is anti-dilutive. Stock options totaling 2.8 million , 1.9 million and 1.0 million for the years ended December 31, 2016 , 2015 and 2014 , respectively, were not included in the computation of diluted EPS because the exercise of such options would be anti-dilutive. As discussed in Note 2, the Company issued its 3.25% Convertible Senior Notes due 2020 (“Convertible Senior Notes”) in December 2014. It is the Company’s intent and policy to settle conversions through combination settlement, which essentially involves repayment of an amount of cash equal to the “principal portion” and delivery of the “share amount” in excess of the conversion value over the principal portion in cash or shares of common stock (“conversion premium”). No conversion premium existed as of December 31, 2016 , 2015 and 2014 ; therefore, there was no dilutive impact from the Convertible Senior Notes to diluted EPS during the years ended December 31, 2016 2015 and 2014 . Comprehensive Loss —Comprehensive loss includes unrealized gains and losses excluded from the Company’s Consolidated Statements of Operations. Use of Estimates —The preparation of financial statements in conformity with accounting principles generally accepted in the U.S. requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Accounting Periods —Each of the Company’s fiscal quarters end on the Sunday closest to the end of the calendar quarter. The Company’s fiscal year ends are January 1, 2017, January 3, 2016 and December 28, 2014. For ease of reference, the calendar quarter end dates are used herein. Recent Accounting Pronouncements —In May 2014, the Financial Accounting Standards Board (“FASB”) issued guidance codified in Accounting Standards Update (“ASU”) 2014-09, Revenue from Contracts with Customers , which amends the guidance in former ASC 605, Revenue Recognition . The standard’s core principle is that a company will recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. In doing so, companies will need to use more judgment and make more estimates than under current authoritative guidance. These may include identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each separate performance obligation. The FASB has issued several amendments to the new standard, which include clarification of accounting guidance related to identification of performance obligations, intellectual property licenses, and principal vs. agent considerations. The standard will be effective for public entities for annual reporting periods beginning after December 15, 2017, including interim periods therein. The Company has assigned internal resources to assist in the adoption of the new standard and is in the initial stages of its evaluation of the impact of the new standard on its accounting policies, processes and system requirements. The Company has begun the process of identifying, categorizing and analyzing its various revenue streams, however, has not yet completed its assessment of the impact. The Company will continue to evaluate the future impact and method of adoption of ASU 2014-09 and related amendments on the Consolidated Financial Statements and related disclosures throughout 2017. The Company will adopt the new standard beginning January 2018. In August 2014, the FASB issued guidance codified in ASU 2014-15 (Subtopic 205-40), Presentation of Financial Statements - Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern . The guidance requires management to evaluate whether there are conditions and events that raise substantial doubt about the entity’s ability to continue as a going concern within one year after the financial statements are issued (or available to be issued when applicable). Management will be required to make this evaluation for both annual and interim reporting periods and will make certain disclosures if it concludes that substantial doubt exists or when its plans alleviate substantial doubt about the entity’s ability to continue as a going concern. Substantial doubt exists when relevant conditions and events, considered in the aggregate, indicate that it is probable that the entity will be unable to meet its obligations as they become due within one year after the date that the financial statements are issued (or available to be issued). The term probable is used consistently with its use in ASC Topic 450, Contingencies . The guidance is effective for annual periods ending after December 15, 2016 and for interim reporting periods starting in the first quarter 2017, with early adoption permitted. The Company's adoption of this guidance in the annual period ended December 31, 2016 did not have an impact on the consolidated financial statements. In February 2015, the FASB issued guidance codified in ASU 2015-02 (Topic 810), Consolidation - Amendments to the Consolidation Analysis . The guidance affects reporting entities that are required to evaluate whether they should consolidate certain legal entities. Specifically, the guidance amends (i) the identification of variable interests (fees paid to a decision maker or service provider), (ii) the variable interest entity (VIE) characteristics for a limited partnership or similar entity and (iii) the primary beneficiary determination. The guidance is effective for annual periods beginning after December 15, 2015 and for interim reporting periods starting in the first quarter 2016. The Company's adoption of this guidance in the first quarter of 2016 did not have a significant impact on the consolidated financial statements. In July 2015, the FASB issued guidance codified in ASU 2015-11 (Topic 330), Simplifying the Measurement of Inventory . The guidance applies to inventory that is measured using first-in, first-out (“FIFO”) or average cost. Under the guidance, an entity should measure inventory that is within scope at the lower of cost and net realizable value, which is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal and transportation. The guidance is effective for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years, with early adoption permitted as of the beginning of an interim or annual reporting period. The Company's adoption of this guidance in the first quarter of 2016 did not have a significant impact on the consolidated financial statements. In February 2016, the FASB issued guidance codified in ASU 2016-02 (Topic 842), Leases . The guidance requires a lessee to recognize a lease liability for the obligation to make lease payments and a right-to-use asset representing the right to use the underlying asset for the lease term on the balance sheet. The guidance is effective for fiscal years beginning after December 15, 2018 including interim periods within those years, with early adoption permitted. The Company is currently evaluating the impact of this guidance and expects to adopt the standard in the first quarter of 2019. In March 2016, the FASB issued guidance codified in ASU 2016-09 (Topic 718), Improvements to Employee Share Based Payments Accounting. Under the guidance, entities will no longer record excess tax benefits and certain tax deficiencies in additional paid-in capital (APIC). Instead, they will record all excess tax benefits and tax deficiencies as income tax expense or benefit in the income statement, and APIC pools will be eliminated. In addition, entities will recognize excess tax benefits regardless of whether the benefit reduces taxes payable in the current period. Under current guidance, excess tax benefits are not recognized until the deduction reduces taxes payable. Companies will apply this part of the guidance using a modified retrospective transition method and will record a cumulative-effect adjustment in retained earnings for excess tax benefits not previously recognized. The guidance also allows an employer to repurchase more of an employee’s shares for tax withholding purposes without triggering liability accounting. The guidance is effective for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years. Early adoption is permitted, but all of the guidance must be adopted in the same period. The Company has excess tax benefits for which a benefit could not be previously recognized of approximately $1.8 million. Upon adoption the balance of the unrecognized excess tax benefits will be reversed with the impact recorded to (accumulated deficit) retained earnings, including any change to the valuation allowance as a result of the adoption. Due to the full valuation allowance on the U.S. deferred tax assets as of December 31, 2016, the Company does not expect any impact to the financial statements as a result of this adoption in the first quarter of 2017.

Debt

Debt	12 Months Ended
	Dec. 31, 2016
Debt Disclosure [Abstract]
Debt	Debt 3.25% Convertible Senior Notes due 2020 In December 2014, the Company issued $172.5 million aggregate principal amount of 3.25% Convertible Senior Notes due 2020. Debt issuance costs of approximately $5.1 million were primarily comprised of underwriters fees, legal, accounting, and other professional fees of which $4.2 million were capitalized and are recorded as a reduction to long-term debt and are being amortized using the effective interest method to interest expense over the six -year term of the Convertible Senior Notes. The remaining $0.9 million of debt issuance costs were allocated as a component of equity in additional paid-in capital. Deferred issuance costs related to the Convertible Senior Notes were $2.8 million and $3.5 million as of December 31, 2016 and 2015 , respectively. The Convertible Senior Notes will be convertible into cash, shares of common stock, or a combination of cash and shares of common stock based on an initial conversion rate, subject to adjustment, of 31.1891 shares per $1,000 principal amount of the Convertible Senior Notes (which represents an initial conversion price of approximately $32.06 per share) on the business day immediately preceding September 15, 2020. This conversion will occur in the following circumstances and to the following extent: (1) during any calendar quarter commencing after the calendar quarter ending on March 31, 2015, if the last reported sales price of the Company's common stock, for at least 20 trading days (whether or not consecutive) in the period of 30 consecutive trading days ending on the last trading day of the calendar quarter immediately preceding the calendar quarter in which the conversion occurs, is more than 130% of the conversion price of the notes in effect on each applicable trading day; (2) during the five consecutive business day period following any five consecutive trading day period in which the trading price per 1,000 principal amount of the Convertible Senior Note for each such trading day was less than 98% of the product of the last reported sale price of the Company's common stock and the conversion rate on each such day; or (3) upon the occurrence of specified events described in the indenture for the Convertible Senior Notes. On or after September 15, 2020 until the close of business on the second scheduled trading day immediately preceding the stated maturity date, holders may surrender their notes for conversion at any time, regardless of the foregoing circumstances. It is the Company’s intent and policy to settle conversions through combination settlement, which essentially involves repayment of an amount of cash equal to the “principal portion” and delivery of the “share amount” in excess of the principal portion in shares of common stock or cash. In general, for each $1,000 in principal, the “principal portion” of cash upon settlement is defined as the lesser of $1,000, and the conversion value during the 25 -day observation period as described in the indenture for the Convertible Senior Notes. The conversion value is the sum of the daily conversion value which is the product of the effective conversion rate divided by 25 days and the daily volume weighted average price (“VWAP”) of the Company’s common stock. The “share amount” is the cumulative “daily share amount” during the observation period, which is calculated by dividing the daily VWAP into the difference between the daily conversion value (i.e., conversion rate x daily VWAP) and $1,000. The Company pays 3.25% interest per annum on the principal amount of the Convertible Senior Notes semi-annually in arrears in cash on June 15 and December 15 of each year. The Convertible Senior Notes mature on December 15, 2020. During the year ended December 31, 2016 , the Company recorded total interest expense of $10.9 million related to the Convertible Senior Notes of which $5.4 million related to the amortization of the debt discount and issuance costs and $5.5 million related to the coupon due semi-annually. During the year ended December 31, 2015 , the Company recorded total interest expense of $10.9 million related to the Convertible Senior Notes of which $5.3 million related to the amortization of the debt discount and issuance costs and $5.6 million related to the coupon due semi-annually. During the year ended December 31, 2014 , the Company recorded total interest expense of $0.6 million related to the Convertible Senior Notes of which $0.3 million related to the amortization of the debt discount and issuance costs and $0.3 million related to the coupon due semi-annually. If a fundamental change, as defined in the indenture for the Convertible Senior Notes, such as an acquisition, merger, or liquidation of the Company, occurs prior to the maturity date, subject to certain limitations, holders of the Convertible Senior Notes may require the Company to repurchase all or a portion of their Convertible Senior Notes for cash at a repurchase price equal to 100% of the principal amount of the Convertible Senior Notes to be repurchased, plus any accrued and unpaid interest to, but excluding, the repurchase date. The Company accounts separately for the liability and equity components of the Convertible Senior Notes in accordance with authoritative guidance for convertible debt instruments that may be settled in cash upon conversion. The guidance requires the carrying amount of the liability component to be estimated by measuring the fair value of a similar liability that does not have an associated conversion feature. Because the Company had no outstanding non-convertible public debt, the Company determined that senior, unsecured corporate bonds traded on the market represent a similar liability to the Convertible Senior Notes without the conversion option. Based on market data available for publicly traded, senior, unsecured corporate bonds issued by companies in the same industry with similar credit ratings and with similar maturity, the Company estimated the implied interest rate of its Convertible Senior Notes to be 6.9% , assuming no conversion option. Assumptions used in the estimate represent what market participants would use in pricing the liability component, which were defined as Level 2 observable inputs. The estimated implied interest rate was applied to the Convertible Senior Notes, which resulted in a fair value of the liability component of $141.9 million upon issuance, calculated as the present value of implied future payments based on the $172.5 million aggregate principal amount. The $30.7 million difference between the cash proceeds of $172.5 million and the estimated fair value of the liability component was recorded in additional paid-in capital, net of tax and issuance costs, as the Convertible Senior Notes were not considered redeemable. In the first quarter of 2016, the Company repurchased and retired $5.2 million in principal amount of the outstanding Convertible Senior Notes. The aggregate cash used for the transaction was $4.5 million . The repurchase resulted in a reduction in debt of $4.4 million and a reduction in additional paid-in capital of $0.5 million with a gain on extinguishment of Convertible Senior Notes of $0.4 million included in interest expense, net in the Consolidated Statements of Operations. The following table summarizes information about the equity and liability components of the Convertible Senior Notes (dollars in thousands). The fair values of the respective notes outstanding were measured based on quoted market prices. December 31, 2016 2015 Principal amount of Convertible Senior Notes outstanding $ 167,314 $ 172,500 Unamortized discount of liability component (20,221 ) (25,703 ) Unamortized deferred issuance costs (2,753 ) (3,500 ) Net carrying amount of liability component 144,340 143,297 Less: current portion — — Long-term debt $ 144,340 $ 143,297 Carrying value of equity component, net of issuance costs $ 29,211 $ 29,758 Fair value of outstanding Convertible Senior Notes $ 165,223 $ 170,120 Remaining amortization period of discount on the liability component 4 years 5 years As a policy election under applicable guidance related to the calculation of diluted net EPS, the Company elected the combination settlement method as its stated settlement policy and applied the treasury stock method in the calculation of dilutive impact of the Convertible Senior Notes. The Convertible Senior Notes were not convertible as of the years ended December 31, 2016 , 2015 and 2014; therefore there was no dilutive impact during the years ended December 31, 2016 , 2015 and 2014. If the Convertible Senior Notes were converted as of December 31, 2016 , the if-converted value would not exceed the principal amount. Line of Credit On August 10, 2012, the Company entered into an amended and restated $140.0 million senior secured syndicated credit facility (the “Senior Credit Facility”), which was set to mature on August 10, 2017 . In connection with this agreement, the Company incurred an additional $1.0 million in deferred financing costs related to the Senior Credit Facility. Deferred financing costs were amortized on a straight-line basis over the term of the Senior Credit Facility and were included as a portion of prepaid expenses and other current assets. On December 1, 2016, the Company voluntarily terminated its Senior Credit Facility and wrote off unamortized deferred financing costs of $0.2 million , which was included in interest expense, net in the Consolidated Statements of Operations for the year ended December 31, 2016 . As of December 31, 2015 , $0.2 million of deferred financing costs were included as a portion of other non-current assets and $0.3 million were included as a portion of prepaid expenses and other current assets.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2016
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes Significant components of the (benefit) provision for income taxes are as follows (in thousands): December 31, 2016 2015 2014 Current: Federal $ (117 ) $ 948 $ 61 State 246 399 (1,294 ) Foreign 84 41 69 Total current provision (benefit) 213 1,388 (1,164 ) Deferred: Federal (2,545 ) (4,624 ) (5,267 ) State (63 ) — 2,488 Foreign 4 18 34 Total deferred benefit (2,604 ) (4,606 ) (2,745 ) Benefit for income taxes $ (2,391 ) $ (3,218 ) $ (3,909 ) The Company’s (loss) income before (benefit) provision for income taxes was subject to taxes in the following jurisdictions for the following periods (in thousands): December 31, 2016 2015 2014 United States $ (16,426 ) $ (9,480 ) $ (11,328 ) Foreign 227 183 345 Loss before benefit for income taxes $ (16,199 ) $ (9,297 ) $ (10,983 ) Significant components of the Company’s deferred tax assets and deferred tax liabilities as of December 31, 2016 and 2015 are shown below (in thousands). December 31, 2016 2015 Deferred tax assets: Net operating loss carryforwards $ 3,255 $ 1,199 Intangible assets 2,351 3,574 Sale-leaseback, net 888 1,224 Allowance for returns and discounts 4,043 4,308 Stock-based compensation 10,963 9,884 Tax credit carryforwards 3,430 2,341 Other, net 4,066 5,200 Total deferred tax assets 28,996 27,730 Valuation allowance for deferred tax assets (7,774 ) (3,087 ) Total deferred tax assets, net of valuation allowance 21,222 24,643 Deferred tax liabilities: Convertible Senior Notes (7,592 ) (9,474 ) Intangible assets (7,557 ) (9,977 ) Property, plant and equipment (6,131 ) (7,162 ) Total deferred tax liabilities (21,280 ) (26,613 ) Net deferred tax liabilities $ (58 ) $ (1,970 ) Management assesses the available positive and negative evidence to estimate if sufficient future taxable income will be generated to use the existing deferred tax assets. A significant piece of objective negative evidence evaluated was the cumulative before-tax loss incurred over the three-year periods ended December 31, 2016 and 2015 . Such objective evidence limits the ability to consider other subjective evidence such as the Company's projections for future profitability. On the basis of this evaluation, as of December 31, 2016 , the Company had recorded a valuation allowance of $7.8 million , which represents the portion of the deferred tax asset that management could no longer conclude was more likely or not to be realized. The amount of the deferred tax assets considered realizable, however, could be adjusted in the future based on changes in available evidence and additional weight may be given to subjective evidence such as the Company's projections for profitability. During the year ended December 31, 2016 , the allowance increased by $4.7 million . The Company recognizes excess tax benefits associated with the exercise of stock options directly to stockholders’ equity only when realized. Accordingly, deferred tax assets are not recognized for net operating loss (“NOL”) carryforwards resulting from excess tax benefits. As of December 31, 2016 and 2015 , deferred tax assets do not include $1.8 million and $1.3 million , respectively, of these excess tax benefits from employee stock option exercises that are a component of the Company’s NOL and tax credit carryforwards. Additional paid-in capital will be increased up to an additional $1.8 million if such excess tax benefits are realized. As discussed in Note 1, upon adoption of ASU 2016-09 in the first quarter of 2017, the balance of the unrecognized excess tax benefits will be reversed with the impact recorded to (accumulated deficit) retained earnings, including any change to the valuation allowance as a result of the adoption. Due to the full valuation allowance on the U.S. deferred tax assets as of December 31, 2016, the Company does not expect any impact to the financial statements as a result of this adoption in the first quarter of 2017. As of December 31, 2016 , the Company had federal NOL carryforwards of approximately $8.3 million which will begin to expire in 2018, unless previously utilized. The Company also had state NOLs of approximately $22.8 million which will begin to expire in 2026, unless previously utilized. The Company has federal research credits of $3.7 million which will begin to expire on December 31, 2031 , unless previously utilized. Additionally, the Company has federal alternative minimum tax credits of $0.5 million which do not expire. The Company also has gross state research credits of $8.9 million , of which $8.7 million do not expire. The remaining $0.2 million begin to expire in 2027, unless previously utilized. Pursuant to Internal Revenue Code (“IRC”) Sections 382 and 383, the Company’s use of its NOL and research credit carryforwards may be limited as a result of cumulative changes in ownership of more than 50% over a three -year period. The benefit for income taxes reconciles to the amount computed by applying the federal statutory rate to loss before taxes as follows (in thousands): Year ended December 31, 2016 2015 2014 Tax benefit at statutory tax rate (5,775 ) (3,254 ) (3,844 ) State tax benefit, net of federal tax benefit (390 ) (235 ) (151 ) Permanent differences 129 157 70 Federal and state research credits—current year (979 ) (722 ) (765 ) Accrual (release) of uncertain tax positions 43 101 (21 ) Expiration of statutes for uncertain tax positions — — (953 ) Impact of change in federal and state tax rate on revaluing deferred tax assets (4 ) 56 110 Change in valuation allowance 4,687 756 2,331 Acquisition related adjustments — — (485 ) Other (102 ) (77 ) (201 ) Benefit for income taxes (2,391 ) (3,218 ) (3,909 ) On December 18, 2015, the Protecting Americans from Tax Hikes Act was signed into law reinstating the federal research and development credit for 2015. Accordingly, we recorded the benefit related to the 2015 federal research and development credit of approximately $0.4 million in the fourth quarter of 2015. The Company considers earnings of its non-U.S. subsidiaries to be indefinitely reinvested in those operations. As of December 31, 2016 , the Company has not made a provision for U.S. or additional foreign withholding taxes on approximately $0.5 million of the excess of the amount for financial reporting over the tax basis of investments in foreign subsidiaries that is indefinitely reinvested. Generally, such amounts become subject to U.S. taxation upon the remittance of dividends and under certain other circumstances. It is not practicable to estimate the amount of deferred tax liability related to investments in these foreign subsidiaries. The Company recognizes liabilities for uncertain tax positions based on a two-step process. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount that is more than 50% likely of being realized upon settlement. While the Company believes that it has appropriate support for the positions taken on its tax returns, the Company regularly assesses the potential outcome of examinations by tax authorities in determining the adequacy of its provision for income taxes. The following table summarizes the activity related to the Company’s unrecognized tax benefits (in thousands): Year ended December 31, 2016 2015 2014 Beginning balance $ 7,684 $ 7,065 $ 7,765 Decreases related to prior year tax positions (10 ) (12 ) (68 ) Increases related to current year tax positions 773 631 642 Decreases due to settlements — — (42 ) Expiration of the statute of limitations for the assessment of taxes — — (1,232 ) Other $ 157 $ — $ — Ending balance $ 8,604 $ 7,684 $ 7,065 As of December 31, 2016 and 2015 , the unrecognized tax benefits of $8.6 million and $7.7 million , respectively, of which $6.4 million and $5.6 million , respectively, would reduce the Company’s annual effective tax rate, subject to the valuation allowance. The Company does not anticipate any significant decreases in its unrecognized tax benefits over the next 12 months. The Company's policy is to recognize the interest expense and penalties related to income tax matters as a component of income tax expense. The Company has accrued approximately $0.2 million of interest and penalties associated with uncertain tax positions for each of the years ended December 31, 2016 and 2015 . There was no interest expense, net of accrued interest (reversed) in 2016. Interest expense, net of accrued interest (reversed) was approximately $0.1 million , and $(0.2) million in 2015 and 2014 , respectively. The Company is subject to periodic audits by domestic and foreign tax authorities. During 2014, the Company released tax reserves and related interest of approximately $1.0 million , net of federal income tax benefits, related to the expiration of the statute of limitation on assessment for certain state matters. Due to the carryforward of unutilized net operating loss and credit carryovers, the Company's federal tax years from 2009 and forward and state tax years 2001 and forward are subject to examination by tax authorities. The Company believes that it has appropriate support for the income tax positions taken on its tax returns and that its accruals for tax liabilities are adequate for all open years based on an assessment of many factors, including past experience and interpretations of tax law applied to the facts of each matter.

Stockholders' Equity

Stockholders' Equity	12 Months Ended
	Dec. 31, 2016
Equity [Abstract]
Stockholders' Equity	Stockholders’ Equity Preferred Stock. The Company’s certificate of incorporation, as amended, authorizes the issuance of up to five million preferred shares. The Board of Directors is authorized to fix the number of shares of any series of preferred stock and to determine the designation of such shares. However, the amended certificate of incorporation specifies the initial series and the rights of that series. No shares of preferred stock were outstanding as of December 31, 2016 , 2015 or 2014. Equity Incentive Plan. The Company grants stock options, time-based restricted stock units (RSUs) and performance-based restricted stock units (PSUs) to employees and non-employee directors under its 2016 Equity Incentive Plan (the “2016 Plan”). The Company previously granted stock options under the Amended and Restated 2010 Equity Incentive Plan (the "2010 Plan") and the Amended and Restated 2001 Equity Incentive Plan (the "2001 Plan"). The 2010 Plan and 2001 Plan were terminated at the time of adoption of the new Plans, but the terminated Plans continue to govern outstanding options granted thereunder. The Company has stock options and RSUs outstanding, which were issued under each of these equity incentive plans to certain employees and directors. Stock options granted under these plans have terms ranging up to ten years, have exercise prices ranging from $8.50 to $27.91 per share, and generally vest over four years. As of December 31, 2016 , approximately 2.6 million shares remained available for grant under the 2016 Plan. Restricted Stock. The Company grants time-based RSUs and PSUs to certain officers, directors and management. Until the restrictions lapse, ownership of the affected RSUs and PSUs granted to the Company’s officers is conditional upon continuous employment with the Company. For the years ended December 31, 2016 , 2015 and 2014 , the Company granted approximately 0.2 million , 0.2 million and 0.1 million shares, respectively, of RSUs to officers and management, which have a time-based four -year vesting provision. For purposes of measuring compensation expense of PSUs, the amount of shares ultimately expected to vest is estimated at each reporting date based on management’s expectations regarding the relevant performance criteria. The recognition of compensation expense associated with the PSUs requires judgment in assessing the probability of meeting the performance goals, as well as defined criteria for assessing achievement of the performance-related goals. The grant date of the PSUs takes place when the grant is authorized and the specific achievement goals are communicated. The communication date of the performance goals can impact the valuation and associated expense of the PSUs. PSUs granted in March 2012 included a three -year vesting cliff based on the achievement of a performance metric tied to earnings per share for the year ended December 31, 2014 . During the fourth quarter ended December 31, 2014 , the Compensation Committee of the Board of Directors amended the performance metric to include adjustments for certain items, some of which are non-recurring. This resulted in a modification of the original award and the Company recorded additional stock-based compensation expense of $0.3 million for the year ended December 31, 2014 . The PSUs granted in March 2012 were released in March 2015 as performance metrics were achieved. There were no PSUs outstanding as of December 31, 2016 or December 31, 2015 . During the years ended December 31, 2016 , 2015 and 2014 , RSUs were granted to certain members of the Board of Directors in lieu of cash compensation as a part of the Company’s non-employee director’s deferred compensation program. The compensation expense associated with these RSU grants were $0.4 million , $0.5 million and $0.4 million for the years ended December 31, 2016 , 2015 and 2014 , respectively. Employee Deferred Bonus Compensation Program. For the years ended December 31, 2016 , 2015 and 2014 , certain employees of the Company were eligible to participate in the Company’s deferred bonus compensation program with respect to any payments received under the Company’s cash incentive plan. Participating employees could elect to receive 50% or 100% of the cash value of their cash bonus in the form of fully vested, restricted stock units plus an additional premium as additional restricted stock units, issued under the 2016 Plan. The premium restricted stock units are subject to a one -year vesting requirement from the date of issuance. The additional premium will be determined based on the length of time of the deferral period selected by the participating employee as follows: (i) if one year from the date of grant, a premium of 10% on the amount deferred, (ii) if two years from the date of grant, a premium of 20% on the amount deferred, or (iii) if four years from the date of grant, a premium of 30% on the amount deferred. Employee Stock Purchase Plan. Under the Company’s Amended and Restated 1983 Employee Stock Purchase Plan (the “ESPP”), full-time employees are allowed to purchase common stock through payroll deductions (which cannot exceed 10% of the employee’s compensation) at the lower of 85% of fair market value at the beginning or end of each six -month purchase period. As of December 31, 2016 , 1,214,175 shares had been sold under the Plan, leaving 285,825 shares available for future issuance. Share Repurchase Program. On January 25, 2016, our Board of Directors authorized an amendment to extend our previously announced stock repurchase program. The Board of Directors has authorized the Company to repurchase up to an aggregate of $50.0 million in shares of our common stock under our stock repurchase program. Any shares of common stock repurchased under this program will no longer be deemed outstanding upon repurchase and will be returned to the pool of authorized shares. During the year ended December 31, 2016 , 1,152,386 shares of outstanding common stock were repurchased under the Company's previously announced share repurchase program for approximately $19.6 million . At December 31, 2016 , $35.0 million remains available under this program. The repurchase program will expire on January 25, 2018 unless extended by the Board of Directors. Shares Reserved for Future Issuance. At December 31, 2016 , approximately 7.0 million shares of common stock were reserved under the Company’s equity incentive plans and 285,825 shares were reserved for purchases under the ESPP.

Stock-Based Compensation

Stock-Based Compensation	12 Months Ended
	Dec. 31, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock-Based Compensation	Stock-Based Compensation For the years ended December 31, 2016 , 2015 and 2014 stock-based compensation expense was $8.0 million , $7.4 million and $6.7 million , respectively, of which $4.7 million , $4.7 million and $4.3 million , respectively, related to stock options and $2.4 million , $2.0 million and $2.1 million , respectively, related to RSUs and PSUs. For the years ended December 31, 2016 , 2015 and 2014 the Company recorded $0.9 million , $0.7 million and $0.3 million in stock-based compensation expense, respectively, associated with the deferred bonus compensation program, described in Note 4. During the years ended December 31, 2016 , 2015 and 2014 , $0.9 million , $0.6 million and $0.3 million , respectively, were initially recorded as a component of accrued payroll and related expenses. Stock-based compensation expense related to stock options, RSUs and PSUs was as follows (in thousands): Year ended December 31, 2016 2015 2014 Cost of sales $ 617 $ 581 $ 609 Research and development 1,551 734 1,062 Sales and marketing 1,189 1,554 1,059 General and administrative 4,629 4,550 3,994 $ 7,986 $ 7,419 $ 6,724 Stock-based compensation expense capitalized to inventory and compensation expense related to the Company’s ESPP were not material for the years ended December 31, 2016 , 2015 and 2014 . Stock Options Compensation expense related to stock options granted is recognized ratably over the service vesting period for the entire option award. For stock options with graded vesting, the Company ensures that the cumulative amount of compensation expense recognized at the end of any reporting period at least equals the portion of the stock option that has vested at that date. The total number of stock options expected to vest is adjusted by estimated forfeiture rates. The estimated fair value of each stock option was determined on the date of grant using the Black-Scholes option valuation model with the following weighted-average assumptions for the option grants: Year ended December 31, 2016 2015 2014 Risk-free interest rate 1.47 % 1.50 % 1.59 % Expected option life (in years) 6.59 6.24 5.78 Volatility rate 36 % 40 % 42 % Dividend rate — % — % — % The computation of the expected option life is based on a weighted-average calculation combining the average life of options that have already been exercised and post-vest cancellations with the estimated life of the remaining vested and unexercised options. The expected volatility is based on the historical volatility of the Company’s stock. The risk-free interest rate is based on the U.S. Treasury yield curve over the expected term of the option. The Company has never paid any cash dividends on its common stock, and does not anticipate paying any cash dividends in the foreseeable future. Consequently, the Company uses an expected dividend yield of zero in the Black-Scholes option valuation model. The Company’s estimated forfeiture rate is based on its historical experience and future expectations. The Company’s determination of fair value is affected by the Company’s stock price as well as a number of assumptions that require judgment. The weighted-average fair value per share was $6.00 , $9.46 and $10.96 for options granted during the years ended December 31, 2016 , 2015 and 2014 , respectively. The total intrinsic value was $4.5 million , $1.6 million and $2.8 million for options exercised during the years ended December 31, 2016 , 2015 and 2014 , respectively. As of December 31, 2016 , total unrecognized compensation expense related to stock options was approximately $5.8 million and the related weighted-average period over which it is expected to be recognized is approximately 2.2 years. The maximum contractual term of the Company’s stock options is ten years. A summary of the status of stock option activity for the years ended December 31, 2014 , 2015 and 2016 is as follows (in thousands, except price data and years): Number of Shares Weighted- average exercise price per share Weighted- average remaining contractual term (in years) Aggregate intrinsic value Outstanding at January 1, 2014 3,474 $ 14.74 Granted 559 26.63 Exercised (251 ) 13.67 Cancelled (175 ) 20.63 Outstanding at December 31, 2014 3,607 16.37 Granted 659 23.15 Exercised (168 ) 12.30 Cancelled (131 ) 23.41 Outstanding at December 31, 2015 3,967 17.44 Granted 677 15.48 Exercised (553 ) 13.76 Cancelled (150 ) 20.86 Outstanding at December 31, 2016 3,941 $ 17.49 5.52 $ 19,236 Vested and expected to vest at December 31, 2016 3,781 $ 17.45 5.38 $ 18,590 Exercisable at December 31, 2016 2,529 $ 15.92 3.95 $ 15,451 Available for future grant at December 31, 2016 2,572 Restricted Stock Units The Company grants both time-based RSUs and PSUs. The fair value of RSUs and PSUs is determined based on the closing market price of the Company’s common stock on the grant date. Compensation expense for RSUs is measured at the grant date and recognized ratably over the vesting period. A portion of the restricted stock granted in 2012 was performance-based and vesting was tied to achievement of specific Company goals in 2014. For purposes of measuring compensation expense for PSUs, the amount of shares ultimately expected to vest was estimated at each reporting date based on management’s expectations regarding the relevant performance criteria. The recognition of compensation expense associated with the PSUs required judgment in assessing the probability of meeting the performance goals, as well as defined criteria for assessing achievement of the performance-related goals. The PSUs granted in March 2012 were released in March 2015. See further discussion of amended performance metrics and the impact to stock-based compensation expense for the year ended December 31, 2014 in Note 4. There was no stock-based compensation expense related to PSUs for the years ended December 31, 2016 or 2015. A summary of the status of stock awards activity for the years ended December 31, 2014 , 2015 and 2016 is as follows (in thousands, except price data): Shares Weighted-average grant date fair value Non-vested at January 1, 2014 454 $ 16.22 Granted 145 25.73 Vested (174 ) 28.27 Forfeited (23 ) 18.19 Non-vested at December 31, 2014 402 14.84 Granted 171 22.79 Vested (96 ) 18.01 Forfeited (18 ) 22.87 Non-vested at December 31, 2015 459 21.61 Granted 185 16.14 Vested (120 ) 18.50 Forfeited (23 ) 20.80 Non-vested at December 31, 2016 501 $ 20.37 In 2016 , 2015 and 2014 , the Company issued approximately 0.1 million restricted share units each year in exchange for the deferred bonus liability of $0.5 million , $0.4 million and $0.7 million , respectively. The total amount of unrecognized compensation expense related to non-vested stock awards as of December 31, 2016 was approximately $3.1 million , which is expected to be recognized over a weighted-average period of approximately 2.4 years.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2016
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Leases The Company leases its facilities and certain equipment. Commitments for minimum rentals under non-cancelable leases at the end of 2016 are as follows (in thousands): Years ending December 31, Operating Leases Lease obligation 2017 $ 2,245 $ 937 2018 2,296 946 2019 2,342 956 2020 2,365 967 2021 2,261 — Thereafter 625 — Total minimum lease payments $ 12,134 $ 3,806 Operating Leases —Rent expense under operating leases totaled approximately $2.2 million for the year ended December 31, 2016 , $2.3 million for the year ended December 31, 2015 and $3.3 million for the year ended December 31, 2014 . In the fourth quarter of 2013 , the Company entered into a lease for approximately 30,000 square feet of office space and moved the executive and administrative functions into this facility in the second quarter of 2014. The lease expires in 2022 with options to extend the lease for two additional five -year periods. This operating lease included a lease incentive for tenant improvements of $1.7 million which has been included as a leasehold improvement in property, plant and equipment and as deferred rent in other current liabilities and non-current deferred rent. McKellar Lease Obligation —During 1999, the Company completed a sale and leaseback transaction of its San Diego facility. The facility was sold for $15.0 million , of which $3.8 million was capital contributed by the Company. The sale was an all cash transaction, netting the Company approximately $7.0 million . The Company is a 25% limited partner in the partnership that acquired the facility. The transaction was deemed a financing transaction under the guidance in ASC Topic 840-40, Accounting for Sales of Real Estate . The assets sold remain on the books of the Company and will continue to be depreciated over the estimated useful life. In December 2009, the Company amended the terms of its lease agreement which had no significant impact on the Company’s financial statements. The amended terms included a new ten -year lease term through December 31, 2019 , with options to extend the lease for up to three additional five -year periods. In the fourth quarter of 2015, the Company amended the terms of its lease agreement to extend the lease term through December 31, 2020. The options to extend the lease for up to three additional five -year periods commence at the new lease term date of December 31, 2020. The Company is amortizing the lease obligation over the new estimated lease term, including extensions. As the Company accounts for the lease as a financing transaction, the Company adjusted the implied interest rate so that the existing lease obligation is amortized to the end of the estimated lease term, including extensions. The Company has determined that the partnership is a variable interest entity (VIE). The Company is not, however, the primary beneficiary of the VIE as it does not absorb the majority of the partnership’s expected losses or receive a majority of the partnership’s residual returns. The Company made lease payments to the partnership of approximately $0.9 million , $1.1 million and $1.1 million for the years ended December 31, 2016 , 2015 and 2014 , respectively. Purchase Commitments The Company has $4.3 million in firm purchase commitments with respect to planned inventory and capital expenditures as of December 31, 2016 . Legal The Company is involved in various claims and litigation matters from time to time in the ordinary course of business. Management believes that all such current legal actions, in the aggregate, will not have a material adverse effect on the Company. The Company also maintains insurance, including coverage for product liability claims, in amounts which management believes are appropriate given the nature of its business. No accrual has been recorded as of December 31, 2016 related to such matters as they are not probable and/or reasonably estimable. At December 31, 2015 , the Company had $0.2 million accrued as a liability for various legal matters where the Company deemed the liability probable and estimable. Licensing Arrangements On September 27, 2011, the Company entered into the Second Amendment (the “Amendment”) to Quidel/Inverness Settlement Agreement dated April 27, 2005 (the “Agreement”), as amended by an Addendum dated June 19, 2006, with Alere Inc. (formerly known as Inverness Medical Innovations, Inc.) (“Alere”). The Amendment, which was effective as of April 1, 2011, amended certain royalty and other provisions in the Agreement and enabled the Company to “buy-down” and “buy-out” its future royalty obligation under the Agreement for payments totaling $29.5 million . Under the Amendment, the Company made an initial cash payment of $13.8 million to Alere in September 2011 in connection with a buy-down of the Company’s royalty obligations for the period beginning July 1, 2011. In addition, the Company exercised its buy-out right for any remaining future royalty obligation by exercising the Royalty Termination Option (as defined in the Amendment) in January 2012, thereby terminating the Company’s obligation to pay future royalties under the Agreement in exchange for a fixed cash payment in the amount of $15.7 million less $1.0 million of specified third quarter 2011 royalties. This amount was paid in February 2012. In conjunction with Financial Accounting Standards Board Accounting Standard Update No. 2009-05, Fair Value Measurements and Disclosures (Topic 820), the Company assigned $28.8 million to the licensed technology and $0.7 million as a one-time charge to cost of sales to settle royalty claims. In determining the fair value allocation between the intangible asset licensed technology and the one-time charge to cost of sales, the Company assessed the past and estimated future revenue streams related to present and future products that use the patents that were subject to the Amendment. The effective life and related amortization of the licensed technology was based on the higher of the percentage of usage or the straight-line method. This percentage of usage was determined using the revenues generated from products covered by the patents that were subject to the Amendment. The terms of the Amendment provide for an estimated useful life of 3.5 years for this asset. The Company recorded $0.7 million of amortization expense in 2015 and $8.0 million in 2014, included as a portion of cost of sales. As of December 31, 2015, this intangible asset has been fully amortized. In addition to the royalty agreement noted above, the Company has entered into various other licensing and royalty agreements, which largely require payments based on specified product sales as well as the achievement of specified milestones. The Company had royalty and license expenses relating to those agreements of approximately $0.8 million , $0.5 million and $0.9 million for the years ended December 31, 2016 , 2015 and 2014 , respectively. Research and Development Agreements The Company has entered into various research and development agreements that provide it with rights to develop, manufacture and market products using the intellectual property and technology of its collaborative partners. Under the terms of certain of these agreements, the Company is required to make periodic payments based on achievement of certain milestones or resource expenditures. These milestones generally include achievement of prototype assays, validation lots and clinical trials. At December 31, 2016 , total future commitments under the terms of these agreements are estimated at $2.3 million . The commitments will fluctuate as the Company agrees to new phases of development under the existing arrangements. Contingent Consideration In conjunction with the acquisition of BioHelix Corporation (“BioHelix”) in May 2013, the Company agreed to contingent consideration ranging from $5.0 million to $10.0 million upon achievement of certain revenue targets through May 2018. The fair value of the royalty revenue earn-out to be settled in cash is estimated using a discounted revenue model. Due to changes in the estimated payments and a shorter discounting period, the fair value of the contingent consideration liabilities changed, resulting in gains of $0.6 million , $21,000 and $0.8 million recorded to cost of sales in the Consolidated Statements of Operations during the years ended December 31, 2016 , 2015 and 2014, respectively. Payments of $0.2 million and $0.1 million related to the revenue royalty earn-out were disbursed during the years ended December 31, 2016 and 2015 , respectively. As of December 31, 2016 , the current portion of the contingent consideration is $2.7 million and the non-current portion of the contingent consideration is $1.9 million . In August 2013, the Company acquired the assets of AnDiaTec GmbH & Co. KG (“AnDiaTec”), a privately-held, diagnostics company, based in Germany. The Company agreed to contingent consideration of up to €0.5 million ( $0.5 million based on the December 31, 2016 currency conversion rate) upon achievement of certain revenue targets through 2018. As of December 31, 2016 , the Company has included $0.1 million in the non-current portion of contingent consideration related to these revenue targets. In addition, the Company agreed to pay the founder of AnDiaTec contingent payments of up to €3.0 million ( $3.1 million based on the December 31, 2016 currency conversion rate) upon achievement of certain research and development milestones, subject to continued employment. The Company paid $0.9 million and $1.7 million for the achievement of agreed upon research and development milestones during the years ended December 31, 2016 and 2015 , respectively. These costs are recorded as compensation expense included in research and development expense in the Consolidated Statements of Operations. As of December 31, 2016 , there are no remaining research and development milestones to be achieved. The Company recorded contingent consideration of $0.4 million related to the acquisition of Immutopics, Inc. ("Immutopics") in March 2016 as discussed in Note 11. In the fourth quarter of 2016, due to changes in the estimated payments, the Company recorded a $0.1 million loss due to the fair value adjustment.

Industry and Geographic Informa

Industry and Geographic Information	12 Months Ended
	Dec. 31, 2016
Segment Reporting [Abstract]
Industry and Geographic Information	Industry and Geographic Information The Company operates in one reportable segment. Sales to customers outside the U.S. represented 17% , 14% and 13% of total revenue for the years ended December 31, 2016 , 2015 and 2014 , respectively. As of December 31, 2016 and 2015 , balances due from foreign customers, in U.S. dollars, were $6.8 million and $5.6 million , respectively. The Company had sales to individual customers in excess of 10% of total revenue, as follows: Year ended December 31, 2016 2015 2014 Customer: A 16 % 20 % 19 % B 15 % 17 % 18 % C 13 % 11 % 11 % 44 % 48 % 48 % As of December 31, 2016 and 2015 , accounts receivable from individual customers with balances due in excess of 10% of total accounts receivable totaled $13.9 million and $12.0 million , respectively. The following presents long-lived assets (excluding intangible assets) and total net revenue by geographic territory (in thousands): Long-lived assets as of December 31, Total revenue for the years ended December 31, 2016 2015 2016 2015 2014 Domestic $ 50,774 $ 52,426 $ 158,244 $ 168,809 $ 159,845 Foreign 84 121 33,359 27,320 24,313 $ 50,858 $ 52,547 $ 191,603 $ 196,129 $ 184,158 Consolidated net revenues by product category are as follows (in thousands): Year ended December 31, 2016 2015 2014 Immunoassays $ 121,416 $ 130,348 $ 118,715 Molecular 9,506 5,424 3,418 Virology 40,083 43,747 44,771 Specialty products 9,387 9,001 7,779 Royalties, grants and other 11,211 7,609 9,475 $ 191,603 $ 196,129 $ 184,158

Fair Value Measurement

Fair Value Measurement	12 Months Ended
	Dec. 31, 2016
Fair Value Disclosures [Abstract]
Fair Value Measurement	Fair Value Measurement The following table presents the Company’s hierarchy for its assets and liabilities measured at fair value on a recurring basis as of the following periods (in thousands): December 31, 2016 December 31, 2015 Level 1 Level 2 Level 3 Total Level 1 Level 2 Level 3 Total Assets: Cash equivalents 133,540 — — 133,540 133,147 — — 133,147 Total assets measured at fair value $ 133,540 $ — $ — $ 133,540 $ 133,147 $ — $ — $ 133,147 Liabilities: Contingent consideration — — 5,175 5,175 — — 5,516 5,516 Total liabilities measured at fair value $ — $ — $ 5,175 $ 5,175 $ — $ — $ 5,516 $ 5,516 There were no transfers of assets or liabilities between Level 1, Level 2 and Level 3 categories of the fair value hierarchy during the years ended December 31, 2016 and 2015 . The Company used Level 1 inputs to determine the fair value of its cash equivalents, which primarily consist of funds held in government money market accounts and commercial paper. As such, the carrying value of cash equivalents approximates fair value. As of December 31, 2016 and 2015 , the carrying value of cash equivalents was $133.5 million and $133.1 million , respectively. The Company assesses the fair value of contingent consideration to be settled in cash related to acquisitions using a discounted revenue model. Significant assumptions used in the measurement include revenue projections and discount rates. This fair value measurement of contingent consideration is based on significant inputs not observed in the market and thus represent Level 3 measurements. In the first quarter of 2016, the Company recorded an additional contingent liability for the acquisition of Immutopics (see Note 11). Due to changes in the estimated payments and a shorter discounting period related to the various contingent consideration liabilities, the fair value of the contingent consideration changed during the years ended December 31, 2016 , 2015 and 2014 (see Note 6). These changes resulted in a $0.5 million gain, $0.1 million gain and $0.9 million gain recorded to cost of sales in the Consolidated Statements of Operations during the years ended December 31, 2016 , 2015 and 2014, respectively. Changes in estimated fair value of contingent consideration liabilities from December 31, 2015 through December 31, 2016 are as follows (in thousands): Contingent consideration liability (Level 3 measurement) Balance at December 31, 2015 $ 5,516 Cash payments (207 ) Net gain recorded for fair value adjustments (485 ) Additional liability recorded for current period acquisition 353 Unrealized gain on foreign currency translation (2 ) Balance at December 31, 2016 $ 5,175

Employee Benefit Plan

Employee Benefit Plan	12 Months Ended
	Dec. 31, 2016
Compensation and Retirement Disclosure [Abstract]
Employee Benefit Plan	Employee Benefit Plan The Company has a defined contribution 401(k) plan (the “401(k) Plan”) covering all employees who are eligible to join the 401(k) Plan upon employment. Employee contributions are subject to a maximum limit by federal law. This Plan includes an employer match of 50% on the first 6% of pay contributed by the employee. The Company contributed approximately $1.5 million , $1.3 million and $1.1 million to the 401(k) Plan during the years ended December 31, 2016 , 2015 and 2014 , respectively.

Impairment Loss

Impairment Loss	12 Months Ended
	Dec. 31, 2016
Goodwill and Intangible Assets Disclosure [Abstract]
Impairment Loss	Impairment Loss The Company originally acquired certain automated direct fluorescent antibody cell analyzer technology as part of its DHI acquisition in 2010. This technology and the related program named "Project Stella" or "Bobcat" continued in development or evaluation (both the technology and associated instrument system) after the acquisition. During the third quarter of 2014, the Company evaluated the potential cash flows related to Project Stella as well as potential sale of the assets or joint development opportunities with third parties. These assets included $1.5 million of software development costs, $1.6 million of in-process research and development, and $0.3 million in manufacturing line costs. Based on the analyses, the Company determined the carrying value was not recoverable and an impairment loss was measured by comparing the carrying value to the estimated fair value of the assets. The fair value of the Project Stella assets was estimated utilizing the discounted cash flow analysis. As a result, the Company recognized an impairment loss of $3.4 million in the third quarter of 2014, included in the Company's Consolidated Statements of Operations. Additionally, $0.2 million was included in the impairment loss related to the expense to terminate a manufacturing contract with a third party to manufacture Project Stella instruments. The Company recorded no further impairment charges for the year ended December 31, 2014 and recorded no impairment charges for the years ended December 31, 2016 and 2015.

Acquisition

Acquisition	12 Months Ended
	Dec. 31, 2016
Business Combinations [Abstract]
Acquisition	Acquisition On March 18, 2016, the Company acquired Immutopics, Inc., a privately-held, life science research company, based in San Clemente, California. The acquisition has been accounted for in conformity with ASC Topic 805, Business Combinations . Total consideration for the acquisition was $5.5 million , which included $5.1 million in initial cash payments and $0.4 million in fair value of contingent consideration based upon achievement of certain revenue targets through September 2024. The Immutopics portfolio of products are included with the Company's specialty products revenue category that serve the bone health research community.

Selected Quarterly Financial Da

Selected Quarterly Financial Data (unaudited)	12 Months Ended
	Dec. 31, 2016
Quarterly Financial Information Disclosure [Abstract]
Selected Quarterly Financial Data (unaudited)	Selected Quarterly Financial Data (unaudited) First Quarter Second Quarter Third Quarter Fourth Quarter (in thousands, except per share data) 2016 Total revenues $ 50,321 $ 39,133 $ 49,341 $ 52,808 Cost of sales (excludes amortization of intangible assets) 19,249 17,318 17,728 19,119 Gross profit (1) 29,482 20,225 30,023 32,001 Total costs and expenses 53,781 48,152 47,216 46,893 Net loss (3,446 ) (7,840 ) (572 ) (1,950 ) Basic and diluted loss per share (0.11 ) (0.24 ) (0.02 ) (0.06 ) 2015 Total revenues $ 61,701 $ 35,204 $ 46,812 $ 52,412 Cost of sales (excludes amortization of intangible assets) 21,112 15,493 16,961 18,122 Gross profit (1) 39,018 18,121 28,261 32,700 Total costs and expenses 53,012 45,029 45,600 49,750 Net income (loss) 3,991 (8,931 ) (762 ) (377 ) Basic net earnings (loss) per share (2) 0.12 (0.26 ) (0.02 ) (0.01 ) Diluted net earnings (loss) per share (2) 0.11 (0.26 ) (0.02 ) (0.01 ) (1) Included in 2016 quarterly gross profit is amortization of intangible assets of $1.6 million , $1.6 million , $1.6 million and $1.7 million for the first quarter, second quarter, third quarter and fourth quarter, respectively. Included in 2015 quarterly gross profit is amortization of intangible assets of $1.6 million , $1.6 million , $1.6 million and $1.5 million for the first quarter, second quarter, third quarter and fourth quarter, respectively. (2) Basic and diluted EPS amounts in each quarter are computed using the weighted-average number of shares outstanding during that quarter, while basic and diluted EPS for the full year is computed using the weighted-average number of shares outstanding during the year. Therefore, the sum of the four quarters’ basic or diluted EPS may not equal the full year basic or diluted EPS.

Consolidated Valuation and Qual

Consolidated Valuation and Qualifying Accounts	12 Months Ended
	Dec. 31, 2016
Valuation and Qualifying Accounts [Abstract]
Consolidated Valuation and Qualifying Accounts	SCHEDULE II QUIDEL CORPORATION CONSOLIDATED VALUATION AND QUALIFYING ACCOUNTS Description Balance at beginning of period Additions charged to expense or as reductions to revenue (1) Deductions (2) Balance at end of period (in thousands) Year ended December 31, 2016 Accounts receivable allowance $ 7,488 $ 28,329 $ (28,652 ) $ 7,165 Year ended December 31, 2015: Accounts receivable allowance $ 8,221 $ 31,532 $ (32,265 ) $ 7,488 Year ended December 31, 2014: Accounts receivable allowance $ 5,790 $ 23,447 $ (21,016 ) $ 8,221 (1) Represents charges associated primarily to accruals for early payment discounts, volume discounts and contract rebates recorded as reductions to revenue. Additions to allowance for doubtful accounts are recorded to sales and marketing expenses. (2) The deductions represent actual charges against the accrual described above.

Company Operations and Summar22

Company Operations and Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2016
Accounting Policies [Abstract]
Consolidation	Consolidation— The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated.
Cash and Cash Equivalents	Cash and Cash Equivalents— The Company considers cash equivalents to be highly liquid investments with a maturity at the date of purchase of three months or less. The Company invests its cash equivalents primarily in money market funds and commercial paper. Cash equivalents are maintained with high quality institutions.
Accounts Receivable	Accounts Receivable— The Company sells its products directly to hospitals and reference laboratories in the U.S. as well as to distributors in the U.S. and internationally (see Note 7). The Company periodically assesses the financial strength of these customers and establishes reserves for anticipated losses when necessary, which historically have not been material. The Company’s reserves primarily consist of amounts related to cash discounts and contract rebates. The balance of accounts receivable is net of reserves of $7.2 million and $7.5 million at December 31, 2016 and 2015 , respectively.
Concentration of Credit Risk	Concentration of Credit Risk— Financial instruments that potentially subject the Company to significant concentrations of credit risk consists principally of trade accounts receivable. The Company performs credit evaluations of its customers’ financial condition and limits the amount of credit extended when deemed necessary, but generally requires no collateral. Credit quality is monitored regularly by reviewing credit history. The Company believes that the concentration of credit risk in its trade accounts receivables is moderated by its credit evaluation process, relatively short collection terms, the high level of credit worthiness of its customers, and letters of credit issued on the Company’s behalf. Potential credit losses are limited to the gross value of accounts receivable.
Inventories	Inventories— Inventories are stated at the lower of cost (first-in, first-out) or net realizable value. The Company reviews the components of its inventory on a quarterly basis for excess, obsolete and impaired inventory and makes appropriate dispositions as obsolete stock is identified.
Property, Plant and Equipment	Property, Plant and Equipment— Property, plant and equipment is recorded at cost and depreciated over the estimated useful lives of the assets ( three to 15 years) using the straight-line method. Amortization of leasehold improvements is computed on the straight-line method over the estimated useful lives of the assets. The total expense for depreciation of fixed assets and amortization of leasehold improvements was $13.4 million , $12.7 million and $10.3 million for the years ended December 31, 2016 , 2015 and 2014 , respectively. Maintenance and minor repairs are charged to operations as incurred.
Intangible Assets	The Company completed its annual evaluation for impairment of goodwill and determined that no impairment of goodwill existed as of December 31, 2016 . Goodwill and Intangible Assets— Intangible assets are recorded at cost and amortized on a straight-line basis over their estimated useful lives, except for software development costs and indefinite-lived intangibles such as goodwill. Software development costs associated with software to be sold, leased or otherwise marketed are expensed as incurred until technological feasibility has been established. After technological feasibility is established, software development costs are capitalized. The capitalized cost is amortized on a straight-line basis over the estimated product life or on the ratio of current revenues to total projected product revenues, whichever is greater.
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets— The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the total book value of an asset may not be recoverable. An impairment loss is recognized when estimated undiscounted future cash flows expected to result from the use of the asset and the eventual disposition are less than its carrying amount. An impairment loss is equal to the excess of the book value of an asset over its determined fair value.
Convertible Debt	Convertible Debt— The Company accounts for convertible debt instruments that may be settled in cash upon conversion (including combination settlement of cash equal to the “principal portion” and delivery of the “share amount” in excess of the conversion value over the principal portion in shares of common stock and/or cash) by separating the liability and equity components of the instruments in a manner that reflects our nonconvertible debt borrowing rate. The Company determines the carrying amount of the liability component by measuring the fair value of similar debt instruments that do not have the conversion feature. If no similar debt instrument exists, the Company estimates fair value by using assumptions that market participants would use in pricing a debt instrument, including market interest rates, credit standing, yield curves and volatilities. Determining the fair value of the debt component requires the use of accounting estimates and assumptions. These estimates and assumptions are judgmental in nature and could have a significant impact on the determination of the debt component, and the associated non-cash interest expense. See Note 2 for additional discussion of the Convertible Senior Notes issued in December 2014.
Revenue Recognition	Revenue Recognition—
Research and Development Costs	Research and Development Costs— Research and development costs are charged to operations as incurred. In conjunction with certain third party service agreements, the Company is required to make periodic payments based on achievement of certain milestones. The costs related to these research and development services are also charged to operations as incurred.
Product Shipment Costs	Product Shipment Costs— Product shipment costs are included in sales and marketing expense in the accompanying Consolidated Statements of Operations.
Advertising Costs	Advertising Costs— Advertising costs are expensed as incurred.
Deferred Rent	Deferred Rent— Rent expense is recorded on a straight-line basis over the term of the lease. The difference between rent expense and amounts paid under the lease agreement are recorded as deferred rent.
Income Taxes	Income Taxes— Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes, using enacted tax rates in effect for the year in which the differences are expected to reverse. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized. The Company’s policy is to recognize the interest expense and penalties related to income tax matters as a component of income tax expense.
Fair Value of Financial Instruments	Fair Value of Financial Instruments — The Company uses the fair value hierarchy established in ASC Topic 820 , Fair Value Measurements and Disclosures, that requires the valuation of assets and liabilities subject to fair value measurements using a three tiered approach and fair value measurement be classified and disclosed by the Company in one of the following three categories: Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities; Level 2: Quoted prices for similar assets and liabilities in active markets, quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e. supported by little or no market activity). The carrying amounts of the Company’s financial instruments, including cash, receivables, accounts payable and accrued liabilities approximate their fair values due to their short-term nature.
Product Warranty	Product Warranty —The Company generally sells products with a limited product warranty and certain limited indemnifications. Due to product testing, the short time between product shipment and the detection and correction of product failures and a low historical rate of payments on indemnification claims, the historical activity and the related expense were not significant for the fiscal years presented.
Stock-Based Compensation	Stock-Based Compensation —Compensation expense related to stock options granted is recognized ratably over the service vesting period for the entire option. The total number of stock options expected to vest is adjusted by estimated forfeiture rates. The Company determined the estimated fair value of each stock option on the date of grant using the Black-Scholes option valuation model. Compensation expense for restricted stock units (RSUs) is measured at the grant date and recognized ratably over the vesting period. The fair value of RSUs is determined based on the closing market price of the Company’s common stock on the grant date.
Earnings Per Share	Computation of (Loss) Earnings Per Share —For the years ended December 31, 2016 , 2015 and 2014 , basic loss per share was computed by dividing net loss by the weighted-average number of common shares outstanding, including restricted stock units vested during the period. Diluted earnings per share (“EPS”) reflects the potential dilution that could occur if the earnings were divided by the weighted-average number of common shares and potentially dilutive common shares from outstanding stock options as well as unvested restricted stock units. Potential dilutive common shares were calculated using the treasury stock method and represent incremental shares issuable upon exercise of the Company’s outstanding stock options and unvested restricted stock units. For the years ended December 31, 2016 , 2015 and 2014 , there were no differences between the number of common shares used for the basic and diluted EPS computation because the Company incurred a net loss and the effect would be anti-dilutive. Stock options and shares of restricted stock that would have been included in the diluted EPS calculation if the Company had earnings amounted to 0.8 million , 1.0 million and 1.1 million for the years ended December 31, 2016 , 2015 and 2014 , respectively. Additionally, stock options are excluded from the calculation of diluted EPS when the combined exercise price, unrecognized stock-based compensation and expected tax benefits upon exercise are greater than the average market price for the Company’s common stock because their effect is anti-dilutive. Stock options totaling 2.8 million , 1.9 million and 1.0 million for the years ended December 31, 2016 , 2015 and 2014 , respectively, were not included in the computation of diluted EPS because the exercise of such options would be anti-dilutive. As discussed in Note 2, the Company issued its 3.25% Convertible Senior Notes due 2020 (“Convertible Senior Notes”) in December 2014. It is the Company’s intent and policy to settle conversions through combination settlement, which essentially involves repayment of an amount of cash equal to the “principal portion” and delivery of the “share amount” in excess of the conversion value over the principal portion in cash or shares of common stock (“conversion premium”). No conversion premium existed as of December 31, 2016 , 2015 and 2014 ; therefore, there was no dilutive impact from the Convertible Senior Notes to diluted EPS during the years ended December 31, 2016 2015 and 2014 .
Comprehensive (Loss) Income	Comprehensive Loss —Comprehensive loss includes unrealized gains and losses excluded from the Company’s Consolidated Statements of Operations.
Use of Estimates	Use of Estimates —The preparation of financial statements in conformity with accounting principles generally accepted in the U.S. requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Accounting Periods	Accounting Periods —Each of the Company’s fiscal quarters end on the Sunday closest to the end of the calendar quarter. The Company’s fiscal year ends are January 1, 2017, January 3, 2016 and December 28, 2014. For ease of reference, the calendar quarter end dates are used herein.
Recent Accounting Pronouncements	Recent Accounting Pronouncements —In May 2014, the Financial Accounting Standards Board (“FASB”) issued guidance codified in Accounting Standards Update (“ASU”) 2014-09, Revenue from Contracts with Customers , which amends the guidance in former ASC 605, Revenue Recognition . The standard’s core principle is that a company will recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. In doing so, companies will need to use more judgment and make more estimates than under current authoritative guidance. These may include identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each separate performance obligation. The FASB has issued several amendments to the new standard, which include clarification of accounting guidance related to identification of performance obligations, intellectual property licenses, and principal vs. agent considerations. The standard will be effective for public entities for annual reporting periods beginning after December 15, 2017, including interim periods therein. The Company has assigned internal resources to assist in the adoption of the new standard and is in the initial stages of its evaluation of the impact of the new standard on its accounting policies, processes and system requirements. The Company has begun the process of identifying, categorizing and analyzing its various revenue streams, however, has not yet completed its assessment of the impact. The Company will continue to evaluate the future impact and method of adoption of ASU 2014-09 and related amendments on the Consolidated Financial Statements and related disclosures throughout 2017. The Company will adopt the new standard beginning January 2018. In August 2014, the FASB issued guidance codified in ASU 2014-15 (Subtopic 205-40), Presentation of Financial Statements - Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern . The guidance requires management to evaluate whether there are conditions and events that raise substantial doubt about the entity’s ability to continue as a going concern within one year after the financial statements are issued (or available to be issued when applicable). Management will be required to make this evaluation for both annual and interim reporting periods and will make certain disclosures if it concludes that substantial doubt exists or when its plans alleviate substantial doubt about the entity’s ability to continue as a going concern. Substantial doubt exists when relevant conditions and events, considered in the aggregate, indicate that it is probable that the entity will be unable to meet its obligations as they become due within one year after the date that the financial statements are issued (or available to be issued). The term probable is used consistently with its use in ASC Topic 450, Contingencies . The guidance is effective for annual periods ending after December 15, 2016 and for interim reporting periods starting in the first quarter 2017, with early adoption permitted. The Company's adoption of this guidance in the annual period ended December 31, 2016 did not have an impact on the consolidated financial statements. In February 2015, the FASB issued guidance codified in ASU 2015-02 (Topic 810), Consolidation - Amendments to the Consolidation Analysis . The guidance affects reporting entities that are required to evaluate whether they should consolidate certain legal entities. Specifically, the guidance amends (i) the identification of variable interests (fees paid to a decision maker or service provider), (ii) the variable interest entity (VIE) characteristics for a limited partnership or similar entity and (iii) the primary beneficiary determination. The guidance is effective for annual periods beginning after December 15, 2015 and for interim reporting periods starting in the first quarter 2016. The Company's adoption of this guidance in the first quarter of 2016 did not have a significant impact on the consolidated financial statements. In July 2015, the FASB issued guidance codified in ASU 2015-11 (Topic 330), Simplifying the Measurement of Inventory . The guidance applies to inventory that is measured using first-in, first-out (“FIFO”) or average cost. Under the guidance, an entity should measure inventory that is within scope at the lower of cost and net realizable value, which is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal and transportation. The guidance is effective for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years, with early adoption permitted as of the beginning of an interim or annual reporting period. The Company's adoption of this guidance in the first quarter of 2016 did not have a significant impact on the consolidated financial statements. In February 2016, the FASB issued guidance codified in ASU 2016-02 (Topic 842), Leases . The guidance requires a lessee to recognize a lease liability for the obligation to make lease payments and a right-to-use asset representing the right to use the underlying asset for the lease term on the balance sheet. The guidance is effective for fiscal years beginning after December 15, 2018 including interim periods within those years, with early adoption permitted. The Company is currently evaluating the impact of this guidance and expects to adopt the standard in the first quarter of 2019. In March 2016, the FASB issued guidance codified in ASU 2016-09 (Topic 718), Improvements to Employee Share Based Payments Accounting. Under the guidance, entities will no longer record excess tax benefits and certain tax deficiencies in additional paid-in capital (APIC). Instead, they will record all excess tax benefits and tax deficiencies as income tax expense or benefit in the income statement, and APIC pools will be eliminated. In addition, entities will recognize excess tax benefits regardless of whether the benefit reduces taxes payable in the current period. Under current guidance, excess tax benefits are not recognized until the deduction reduces taxes payable. Companies will apply this part of the guidance using a modified retrospective transition method and will record a cumulative-effect adjustment in retained earnings for excess tax benefits not previously recognized. The guidance also allows an employer to repurchase more of an employee’s shares for tax withholding purposes without triggering liability accounting. The guidance is effective for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years. Early adoption is permitted, but all of the guidance must be adopted in the same period. The Company has excess tax benefits for which a benefit could not be previously recognized of approximately $1.8 million. Upon adoption the balance of the unrecognized excess tax benefits will be reversed with the impact recorded to (accumulated deficit) retained earnings, including any change to the valuation allowance as a result of the adoption. Due to the full valuation allowance on the U.S. deferred tax assets as of December 31, 2016, the Company does not expect any impact to the financial statements as a result of this adoption in the first quarter of 2017.
Fair Value Measurements and Disclosures	In conjunction with Financial Accounting Standards Board Accounting Standard Update No. 2009-05, Fair Value Measurements and Disclosures (Topic 820), the Company assigned $28.8 million to the licensed technology and $0.7 million as a one-time charge to cost of sales to settle royalty claims. In determining the fair value allocation between the intangible asset licensed technology and the one-time charge to cost of sales, the Company assessed the past and estimated future revenue streams related to present and future products that use the patents that were subject to the Amendment. The effective life and related amortization of the licensed technology was based on the higher of the percentage of usage or the straight-line method. This percentage of usage was determined using the revenues generated from products covered by the patents that were subject to the Amendment. The terms of the Amendment provide for an estimated useful life of 3.5 years for this asset.

Company Operations and Summar23

Company Operations and Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2016
Accounting Policies [Abstract]
Summary of Inventories	Inventories consisted of the following, net of reserves of $0.7 million at December 31, 2016 and 2015 (in thousands): December 31, 2016 2015 Raw materials $ 9,297 $ 10,289 Work-in-process (materials, labor and overhead) 7,990 7,441 Finished goods (materials, labor and overhead) 8,758 8,658 Total inventories $ 26,045 $ 26,388
Property, Plant and Equipment	Property, plant and equipment consisted of the following (in thousands): December 31, 2016 2015 Equipment, furniture and fixtures $ 61,972 $ 59,736 Building and improvements 34,243 33,048 Leased instruments 24,014 18,280 Land 1,080 1,080 Total property, plant and equipment, gross 121,309 112,144 Less: accumulated depreciation and amortization (70,451 ) (59,597 ) Total property, plant and equipment, net $ 50,858 $ 52,547
Summary of Intangible Assets	oodwill of $83.8 million as of December 31, 2016 and $80.7 million as of December 31, 2015 . Intangible assets consisted of the following (dollar amounts in thousands): December 31, 2016 December 31, 2015 Description Weighted-average useful life (years) Gross assets Accumulated amortization Net Gross assets Accumulated amortization Net Purchased technology 8.4 53,600 (41,369 ) 12,231 52,560 (34,911 ) 17,649 Customer relationships 7.6 7,157 (5,928 ) 1,229 7,171 (4,972 ) 2,199 License agreements 10.4 6,009 (3,222 ) 2,787 5,512 (2,542 ) 2,970 Patent and trademark costs 12.0 11,240 (3,522 ) 7,718 10,530 (2,588 ) 7,942 Software development costs 5 6,000 (2,326 ) 3,674 2,913 (1,840 ) 1,073 Total intangible assets $ 84,006 $ (56,367 ) $ 27,639 $ 78,686 $ (46,853 ) $ 31,833
Summary of Expected Future Annual Amortization Expense	The expected future annual amortization expense of the Company’s intangible assets is as follows (in thousands): For the years ending December 31, Amortization expense 2017 $ 9,822 2018 4,332 2019 3,079 2020 2,700 2021 2,582 Thereafter 5,124 Total $ 27,639
Schedule of Other Current Liabilities	Other current liabilities— Other current liabilities consisted of the following (in thousands): December 31, 2016 2015 Customer incentives $ 3,766 $ 4,030 Accrued interest 227 202 Other 1,006 2,767 Total other current liabilities $ 4,999 $ 6,999

Debt Tables (Tables)

Debt Tables (Tables)	12 Months Ended
	Dec. 31, 2016
Debt Disclosure [Abstract]
Schedule of Long-term Debt Instruments	The following table summarizes information about the equity and liability components of the Convertible Senior Notes (dollars in thousands). The fair values of the respective notes outstanding were measured based on quoted market prices. December 31, 2016 2015 Principal amount of Convertible Senior Notes outstanding $ 167,314 $ 172,500 Unamortized discount of liability component (20,221 ) (25,703 ) Unamortized deferred issuance costs (2,753 ) (3,500 ) Net carrying amount of liability component 144,340 143,297 Less: current portion — — Long-term debt $ 144,340 $ 143,297 Carrying value of equity component, net of issuance costs $ 29,211 $ 29,758 Fair value of outstanding Convertible Senior Notes $ 165,223 $ 170,120 Remaining amortization period of discount on the liability component 4 years 5 years

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2016
Income Tax Disclosure [Abstract]
Components of (Benefit) Provision for Income Taxes	Significant components of the (benefit) provision for income taxes are as follows (in thousands): December 31, 2016 2015 2014 Current: Federal $ (117 ) $ 948 $ 61 State 246 399 (1,294 ) Foreign 84 41 69 Total current provision (benefit) 213 1,388 (1,164 ) Deferred: Federal (2,545 ) (4,624 ) (5,267 ) State (63 ) — 2,488 Foreign 4 18 34 Total deferred benefit (2,604 ) (4,606 ) (2,745 ) Benefit for income taxes $ (2,391 ) $ (3,218 ) $ (3,909 )
Schedule of Income before (Benefit) Provision for Income Taxes	The Company’s (loss) income before (benefit) provision for income taxes was subject to taxes in the following jurisdictions for the following periods (in thousands): December 31, 2016 2015 2014 United States $ (16,426 ) $ (9,480 ) $ (11,328 ) Foreign 227 183 345 Loss before benefit for income taxes $ (16,199 ) $ (9,297 ) $ (10,983 )
Schedule of Deferred Tax Assets and Liabilities	Significant components of the Company’s deferred tax assets and deferred tax liabilities as of December 31, 2016 and 2015 are shown below (in thousands). December 31, 2016 2015 Deferred tax assets: Net operating loss carryforwards $ 3,255 $ 1,199 Intangible assets 2,351 3,574 Sale-leaseback, net 888 1,224 Allowance for returns and discounts 4,043 4,308 Stock-based compensation 10,963 9,884 Tax credit carryforwards 3,430 2,341 Other, net 4,066 5,200 Total deferred tax assets 28,996 27,730 Valuation allowance for deferred tax assets (7,774 ) (3,087 ) Total deferred tax assets, net of valuation allowance 21,222 24,643 Deferred tax liabilities: Convertible Senior Notes (7,592 ) (9,474 ) Intangible assets (7,557 ) (9,977 ) Property, plant and equipment (6,131 ) (7,162 ) Total deferred tax liabilities (21,280 ) (26,613 ) Net deferred tax liabilities $ (58 ) $ (1,970 )
Reconciliation of Income Tax Computed at Federal Statutory Rate	Year ended December 31, 2016 2015 2014 Tax benefit at statutory tax rate (5,775 ) (3,254 ) (3,844 ) State tax benefit, net of federal tax benefit (390 ) (235 ) (151 ) Permanent differences 129 157 70 Federal and state research credits—current year (979 ) (722 ) (765 ) Accrual (release) of uncertain tax positions 43 101 (21 ) Expiration of statutes for uncertain tax positions — — (953 ) Impact of change in federal and state tax rate on revaluing deferred tax assets (4 ) 56 110 Change in valuation allowance 4,687 756 2,331 Acquisition related adjustments — — (485 ) Other (102 ) (77 ) (201 ) Benefit for income taxes (2,391 ) (3,218 ) (3,909 )
Summary of Unrecognized Tax Benefits	The following table summarizes the activity related to the Company’s unrecognized tax benefits (in thousands): Year ended December 31, 2016 2015 2014 Beginning balance $ 7,684 $ 7,065 $ 7,765 Decreases related to prior year tax positions (10 ) (12 ) (68 ) Increases related to current year tax positions 773 631 642 Decreases due to settlements — — (42 ) Expiration of the statute of limitations for the assessment of taxes — — (1,232 ) Other $ 157 $ — $ — Ending balance $ 8,604 $ 7,684 $ 7,065

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	12 Months Ended
	Dec. 31, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Compensation Expense Related to Stock-Based Compensation Plans	tock-based compensation expense related to stock options, RSUs and PSUs was as follows (in thousands): Year ended December 31, 2016 2015 2014 Cost of sales $ 617 $ 581 $ 609 Research and development 1,551 734 1,062 Sales and marketing 1,189 1,554 1,059 General and administrative 4,629 4,550 3,994 $ 7,986 $ 7,419 $ 6,724
Estimated Fair Value of Each Stock Option Award	The estimated fair value of each stock option was determined on the date of grant using the Black-Scholes option valuation model with the following weighted-average assumptions for the option grants: Year ended December 31, 2016 2015 2014 Risk-free interest rate 1.47 % 1.50 % 1.59 % Expected option life (in years) 6.59 6.24 5.78 Volatility rate 36 % 40 % 42 % Dividend rate — % — % — %
Summary of Status of Stock Option Activity	A summary of the status of stock option activity for the years ended December 31, 2014 , 2015 and 2016 is as follows (in thousands, except price data and years): Number of Shares Weighted- average exercise price per share Weighted- average remaining contractual term (in years) Aggregate intrinsic value Outstanding at January 1, 2014 3,474 $ 14.74 Granted 559 26.63 Exercised (251 ) 13.67 Cancelled (175 ) 20.63 Outstanding at December 31, 2014 3,607 16.37 Granted 659 23.15 Exercised (168 ) 12.30 Cancelled (131 ) 23.41 Outstanding at December 31, 2015 3,967 17.44 Granted 677 15.48 Exercised (553 ) 13.76 Cancelled (150 ) 20.86 Outstanding at December 31, 2016 3,941 $ 17.49 5.52 $ 19,236 Vested and expected to vest at December 31, 2016 3,781 $ 17.45 5.38 $ 18,590 Exercisable at December 31, 2016 2,529 $ 15.92 3.95 $ 15,451 Available for future grant at December 31, 2016 2,572
Summary of Status of Stock Awards Activity	A summary of the status of stock awards activity for the years ended December 31, 2014 , 2015 and 2016 is as follows (in thousands, except price data): Shares Weighted-average grant date fair value Non-vested at January 1, 2014 454 $ 16.22 Granted 145 25.73 Vested (174 ) 28.27 Forfeited (23 ) 18.19 Non-vested at December 31, 2014 402 14.84 Granted 171 22.79 Vested (96 ) 18.01 Forfeited (18 ) 22.87 Non-vested at December 31, 2015 459 21.61 Granted 185 16.14 Vested (120 ) 18.50 Forfeited (23 ) 20.80 Non-vested at December 31, 2016 501 $ 20.37

Commitments and Contingencies (

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2016
Commitments and Contingencies Disclosure [Abstract]
Commitments for Minimum Rentals under Non-cancelable Leases	The Company leases its facilities and certain equipment. Commitments for minimum rentals under non-cancelable leases at the end of 2016 are as follows (in thousands): Years ending December 31, Operating Leases Lease obligation 2017 $ 2,245 $ 937 2018 2,296 946 2019 2,342 956 2020 2,365 967 2021 2,261 — Thereafter 625 — Total minimum lease payments $ 12,134 $ 3,806

Industry and Geographic Infor28

Industry and Geographic Information (Tables)	12 Months Ended
	Dec. 31, 2016
Segment Reporting [Abstract]
Sales to Individual Customers in Excess of 10% of Total Revenue	The Company had sales to individual customers in excess of 10% of total revenue, as follows: Year ended December 31, 2016 2015 2014 Customer: A 16 % 20 % 19 % B 15 % 17 % 18 % C 13 % 11 % 11 % 44 % 48 % 48 %
Long-Lived Assets (Excluding Intangible Assets) and Total Net Revenue	The following presents long-lived assets (excluding intangible assets) and total net revenue by geographic territory (in thousands): Long-lived assets as of December 31, Total revenue for the years ended December 31, 2016 2015 2016 2015 2014 Domestic $ 50,774 $ 52,426 $ 158,244 $ 168,809 $ 159,845 Foreign 84 121 33,359 27,320 24,313 $ 50,858 $ 52,547 $ 191,603 $ 196,129 $ 184,158
Consolidated Net Product Revenues by Disease State	Consolidated net revenues by product category are as follows (in thousands): Year ended December 31, 2016 2015 2014 Immunoassays $ 121,416 $ 130,348 $ 118,715 Molecular 9,506 5,424 3,418 Virology 40,083 43,747 44,771 Specialty products 9,387 9,001 7,779 Royalties, grants and other 11,211 7,609 9,475 $ 191,603 $ 196,129 $ 184,158

Fair Value Measurement (Tables)

Fair Value Measurement (Tables)	12 Months Ended
	Dec. 31, 2016
Fair Value Disclosures [Abstract]
Assets and Liabilities Measured at Fair Value on Recurring Basis	The following table presents the Company’s hierarchy for its assets and liabilities measured at fair value on a recurring basis as of the following periods (in thousands): December 31, 2016 December 31, 2015 Level 1 Level 2 Level 3 Total Level 1 Level 2 Level 3 Total Assets: Cash equivalents 133,540 — — 133,540 133,147 — — 133,147 Total assets measured at fair value $ 133,540 $ — $ — $ 133,540 $ 133,147 $ — $ — $ 133,147 Liabilities: Contingent consideration — — 5,175 5,175 — — 5,516 5,516 Total liabilities measured at fair value $ — $ — $ 5,175 $ 5,175 $ — $ — $ 5,516 $ 5,516
Changes in Estimated Fair Value of Contingent Consideration Liabilities	Changes in estimated fair value of contingent consideration liabilities from December 31, 2015 through December 31, 2016 are as follows (in thousands): Contingent consideration liability (Level 3 measurement) Balance at December 31, 2015 $ 5,516 Cash payments (207 ) Net gain recorded for fair value adjustments (485 ) Additional liability recorded for current period acquisition 353 Unrealized gain on foreign currency translation (2 ) Balance at December 31, 2016 $ 5,175

Selected Quarterly Financial 30

Selected Quarterly Financial Data (unaudited) (Tables)	12 Months Ended
	Dec. 31, 2016
Quarterly Financial Information Disclosure [Abstract]
Quarterly Financial Data	First Quarter Second Quarter Third Quarter Fourth Quarter (in thousands, except per share data) 2016 Total revenues $ 50,321 $ 39,133 $ 49,341 $ 52,808 Cost of sales (excludes amortization of intangible assets) 19,249 17,318 17,728 19,119 Gross profit (1) 29,482 20,225 30,023 32,001 Total costs and expenses 53,781 48,152 47,216 46,893 Net loss (3,446 ) (7,840 ) (572 ) (1,950 ) Basic and diluted loss per share (0.11 ) (0.24 ) (0.02 ) (0.06 ) 2015 Total revenues $ 61,701 $ 35,204 $ 46,812 $ 52,412 Cost of sales (excludes amortization of intangible assets) 21,112 15,493 16,961 18,122 Gross profit (1) 39,018 18,121 28,261 32,700 Total costs and expenses 53,012 45,029 45,600 49,750 Net income (loss) 3,991 (8,931 ) (762 ) (377 ) Basic net earnings (loss) per share (2) 0.12 (0.26 ) (0.02 ) (0.01 ) Diluted net earnings (loss) per share (2) 0.11 (0.26 ) (0.02 ) (0.01 ) (1) Included in 2016 quarterly gross profit is amortization of intangible assets of $1.6 million , $1.6 million , $1.6 million and $1.7 million for the first quarter, second quarter, third quarter and fourth quarter, respectively. Included in 2015 quarterly gross profit is amortization of intangible assets of $1.6 million , $1.6 million , $1.6 million and $1.5 million for the first quarter, second quarter, third quarter and fourth quarter, respectively. (2) Basic and diluted EPS amounts in each quarter are computed using the weighted-average number of shares outstanding during that quarter, while basic and diluted EPS for the full year is computed using the weighted-average number of shares outstanding during the year. Therefore, the sum of the four quarters’ basic or diluted EPS may not equal the full year basic or diluted EPS. First Quarter Second Quarter Third Quarter Fourth Quarter (in thousands, except per share data) 2016 Total revenues $ 50,321 $ 39,133 $ 49,341 $ 52,808 Cost of sales (excludes amortization of intangible assets) 19,249 17,318 17,728 19,119 Gross profit (1) 29,482 20,225 30,023 32,001 Total costs and expenses 53,781 48,152 47,216 46,893 Net loss (3,446 ) (7,840 ) (572 ) (1,950 ) Basic and diluted loss per share (0.11 ) (0.24 ) (0.02 ) (0.06 ) 2015 Total revenues $ 61,701 $ 35,204 $ 46,812 $ 52,412 Cost of sales (excludes amortization of intangible assets) 21,112 15,493 16,961 18,122 Gross profit (1) 39,018 18,121 28,261 32,700 Total costs and expenses 53,012 45,029 45,600 49,750 Net income (loss) 3,991 (8,931 ) (762 ) (377 ) Basic net earnings (loss) per share (2) 0.12 (0.26 ) (0.02 ) (0.01 ) Diluted net earnings (loss) per share (2) 0.11 (0.26 ) (0.02 ) (0.01 )

Company Operations and Summar31

Company Operations and Summary of Significant Accounting Policies - Additional Information (Detail) $ in Thousands, shares in Millions	Sep. 10, 2014USD ($)	Nov. 06, 2012USD ($)	Jul. 31, 2016USD ($)	Apr. 30, 2015USD ($)	Dec. 31, 2014USD ($)	Sep. 30, 2014USD ($)	Dec. 31, 2016USD ($)Segmentshares	Dec. 31, 2015USD ($)shares	Dec. 31, 2014USD ($)shares	Dec. 31, 2016USD ($)
Acquired Finite-Lived Intangible Assets [Line Items]
Number of business segment | Segment							1
Cash and cash equivalents maximum maturity period							3 months
Product shipment costs					$ 3,800		$ 3,800	$ 3,900
Excluded from computation of earnings per share, amount | shares							0.8	1	1.1
Account receivable, reserves							$ 7,200	$ 7,500		$ 7,200
Advertising cost expensed					400		300	700
Revenue recognition milestone method payment received	$ 10,600		$ 2,800	$ 2,400				2,500
Maximum amount of milestone based grant related to research and commercialization activities	$ 12,600	$ 8,300
Amortization expense							9,500	10,200	$ 17,400
Net of reserves, inventories							700			700
Depreciation and amortization							13,400	12,700	10,300
Impairment loss							0	0	3,558
Fund received for research and development activities		$ 2,600
Company's grant revenue							$ 6,500	5,100	6,300	$ 20,900
Finite-Lived intangible asset, useful life							3 years 6 months
Other Noncurrent Liabilities [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Prior period reclassification adjustment								700
Software development costs [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Finite-Lived intangible asset, useful life							5 years
Capitalized Software Costs [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Amortization expense							$ 500	600	600
License agreements [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Amortization expense					$ 8,000			700	8,000
Finite-Lived intangible asset, useful life							10 years 4 months 24 days
License agreements [Member] | Cost of sales [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Amortization expense								$ 700	$ 8,000
Minimum [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Estimated useful lives of the assets							3 years
Maximum [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Estimated useful lives of the assets							15 years
Software and Software Development Costs [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Impairment loss						$ 1,500

Company Operations and Summar32

Company Operations and Summary of Significant Accounting Policies - Summary of Inventories (Detail) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Inventory Disclosure [Abstract]
Raw materials	$ 9,297	$ 10,289
Work-in-process (materials, labor and overhead)	7,990	7,441
Finished goods (materials, labor and overhead)	8,758	8,658
Total inventories	$ 26,045	$ 26,388

Company Operations and Summar33

Company Operations and Summary of Significant Accounting Policies - Property, Plant and equipment (Detail) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 121,309	$ 112,144
Less: accumulated depreciation and amortization	(70,451)	(59,597)
Total property, plant and equipment, net	50,858	52,547
Equipment, furniture and fixtures [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	61,972	59,736
Building and building improvements [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	34,243	33,048
Instruments available for lease [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	24,014	18,280
Land [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 1,080	$ 1,080

Company Operations and Summar34

Company Operations and Summary of Significant Accounting Policies - Summary of Intangible Assets (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Goodwill And Intangible Assets [Line Items]
Goodwill Net	$ 83,834	$ 80,730
Finite-Lived intangible asset, useful life	3 years 6 months
Accumulated Amortization	$ (56,367)	(46,853)
Total	27,639
Gross intangible asset including Goodwill	84,006	78,686
Net intangible asset including Goodwill	$ 27,639	31,833
Purchased technology [Member]
Goodwill And Intangible Assets [Line Items]
Finite-Lived intangible asset, useful life	8 years 4 months 24 days
Gross Assets	$ 53,600	52,560
Accumulated Amortization	(41,369)	(34,911)
Total	$ 12,231	17,649
Customer relationships [Member]
Goodwill And Intangible Assets [Line Items]
Finite-Lived intangible asset, useful life	7 years 6 months 30 days
Gross Assets	$ 7,157	7,171
Accumulated Amortization	(5,928)	(4,972)
Total	$ 1,229	2,199
License agreements [Member]
Goodwill And Intangible Assets [Line Items]
Finite-Lived intangible asset, useful life	10 years 4 months 24 days
Gross Assets	$ 6,009	5,512
Accumulated Amortization	(3,222)	(2,542)
Total	$ 2,787	2,970
Patent and trademark costs [Member]
Goodwill And Intangible Assets [Line Items]
Finite-Lived intangible asset, useful life	12 years
Gross Assets	$ 11,240	10,530
Accumulated Amortization	(3,522)	(2,588)
Total	$ 7,718	7,942
Software development costs [Member]
Goodwill And Intangible Assets [Line Items]
Finite-Lived intangible asset, useful life	5 years
Gross Assets	$ 6,000	2,913
Accumulated Amortization	(2,326)	(1,840)
Total	$ 3,674	$ 1,073

Company Operations and Summar35

Company Operations and Summary of Significant Accounting Policies - Summary of Expected Future Annual Amortization Expense (Detail) $ in Thousands	Dec. 31, 2016USD ($)
Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]
2,017	$ 9,822
2,018	4,332
2,019	3,079
2,020	2,700
2,021	2,582
Thereafter	5,124
Total	$ 27,639

Company Operations and Summar36

Company Operations and Summary of Significant Accounting Policies - Other Current Liabilities (Detail) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Other Liabilities Disclosure [Abstract]
Customer incentives	$ 3,766	$ 4,030
Accrued interest	227	202
Other	1,006	2,767
Total other current liabilities	$ 4,999	$ 6,999

Company Operations and Summar37

Company Operations and Summary of Significant Accounting Policies - Basic and Diluted EPS (Detail) - shares shares in Millions	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Earnings Per Share [Abstract]
Excluded from computation of earnings per share, amount	0.8	1	1.1
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	2.8	1.9	1

Debt Convertible Senior Notes (

Debt Convertible Senior Notes (Details) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2016USD ($)d	Dec. 31, 2015USD ($)$ / shares	Dec. 31, 2014USD ($)	Dec. 08, 2014USD ($)
Debt Instrument [Line Items]
Interest expense, Convertible Senior Notes, Amortization		$ 5,300
Interest Expense, Debt	$ 10,900	10,900	$ 600
Proceeds from issuance of Convertible Senior Notes	0	0	172,500
Repurchase of Convertible Debt	547
Repayments of Convertible Debt	4,459	0	0
Gain on extinguishment of Convertible Senior Notes	(421)	0	0
Other Current Assets [Member]
Debt Instrument [Line Items]
Deferred financing costs		300
Other non-current assets [Member]
Debt Instrument [Line Items]
Deferred financing costs			200
3.25% Convertible Senior Notes due 2020 [Member] | Convertible Debt [Member]
Debt Instrument [Line Items]
Convertible Senior Notes, face amount		$ 172,500		$ 172,500
Convertible Senior Notes, interest rate, stated percentage		3.25%
Debt issuance cost		$ 5,100
Deferred financing costs		$ 4,200
Remaining amortization period of discount on the liability component		6 years
Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs	900
Debt Instrument, Unamortized Discount	$ 20,221	$ 25,703
Convertible Senior Notes, conversion ratio	31.1891
Convertible Senior Notes, conversion price (in dollars per share) | $ / shares		$ 32.06
Convertible Senior Notes, threshold trading days | d	20
Convertible Senior Notes, threshold consecutive trading days	30 years
Convertible Senior Notes, threshold percentage of stock price trigger	130.00%
Convertible Senior Notes, threshold consecutive business days	5 years
Debt Instrument, Convertible, Threshold Consecutive Trading Days, Following Consecutive Business Days	5 years
Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger, Following Consecutive Business Days	98.00%
Convertible Senior Notes, observation period	25 years
Carrying value of equity component, net of issuance costs	$ 29,211	$ 29,758		30,700
Interest expense, Convertible Senior Notes, Amortization	5,400		300
Interest expense, Convertible Senior Notes	$ 5,500	5,600	$ 300
Debt Conversion, Converted Instrument, Rate	100.00%
Debt Instrument, Interest Rate, Effective Percentage	6.90%
Convertible Senior Notes, fair value disclosures				$ 141,900
Proceeds from issuance of Convertible Senior Notes	$ 172,500
Fair value of outstanding Convertible Senior Notes	165,223	170,120
Repurchase of Convertible Debt	5,200
Repayments of Convertible Debt	4,500
Repayments of Debt	4,400
Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt, Subsequent Adjustments	500
Gain on extinguishment of Convertible Senior Notes	(400)
3.25% Convertible Senior Notes due 2020 [Member] | Other Current Assets [Member] | Convertible Debt [Member]
Debt Instrument [Line Items]
Deferred financing costs	$ 2,753	$ 3,500

Debt Debt schedule (Details)

Debt Debt schedule (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014	Dec. 08, 2014
Debt Instrument [Line Items]
Long-term debt	$ 144,340	$ 143,297
Convertible Debt [Member] | 3.25% Convertible Senior Notes due 2020 [Member]
Debt Instrument [Line Items]
Principal amount of Convertible Senior Notes outstanding	167,314	172,500
Unamortized deferred issuance costs	(20,221)	(25,703)
Unamortized deferred issuance costs		(4,200)
Net carrying amount of liability component	144,340	143,297
Less: current portion	0	0
Long-term debt	144,340	143,297
Carrying value of equity component, net of issuance costs	29,211	29,758		$ 30,700
Fair value of outstanding Convertible Senior Notes	$ 165,223	$ 170,120
Remaining amortization period of discount on the liability component	4 years	5 years
Other non-current assets [Member]
Debt Instrument [Line Items]
Unamortized deferred issuance costs			$ (200)

Line of Credit (Detail)

Line of Credit (Detail) - USD ($)	1 Months Ended	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014	Aug. 10, 2012
Line of Credit Facility [Line Items]
Write off of Deferred Debt Issuance Cost	$ 200,000
Other non-current assets [Member]
Line of Credit Facility [Line Items]
Deferred financing costs				$ 200,000
Other Current Assets [Member]
Line of Credit Facility [Line Items]
Deferred financing costs			$ 300,000
Senior Credit Facility [Member]
Line of Credit Facility [Line Items]
Senior Credit Facility					$ 140,000,000
Deferred financing costs			$ 1,000,000
Senior Credit Facility, maturity date		Aug. 10, 2017

Income Taxes - Components of (B

Income Taxes - Components of (Benefit) Provision for Income Taxes (Detail) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Current:
Federal		$ (117)	$ 948	$ 61
State		246	399	(1,294)
Foreign		84	41	69
Total current provision (benefit)		213	1,388	(1,164)
Deferred:
Federal		(2,545)	(4,624)	(5,267)
State		(63)	0	2,488
Foreign		4	18	34
Total deferred benefit		(2,604)	(4,606)	(2,745)
Benefit for income taxes	$ (3,909)	$ (2,391)	$ (3,218)	$ (3,909)

Income Taxes - Schedule of Inco

Income Taxes - Schedule of Income before (Benefit) Provision for Income Taxes (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Income Tax Disclosure [Abstract]
United States	$ (16,426)	$ (9,480)	$ (11,328)
Foreign	227	183	345
Loss before benefit for income taxes	$ (16,199)	$ (9,297)	$ (10,983)

Income Taxes - Schedule of Defe

Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Detail) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Deferred tax assets:
Net operating loss carryforwards	$ 3,255	$ 1,199
Intangible assets	2,351	3,574
Sale-leaseback, net	888	1,224
Allowance for returns and discounts	4,043	4,308
Stock-based compensation	10,963	9,884
Tax credit carryforwards	3,430	2,341
Other, net	4,066	5,200
Total deferred tax assets	28,996	27,730
Valuation allowance for deferred tax assets	(7,774)	(3,087)
Total deferred tax assets	21,222	24,643
Deferred tax liabilities:
Convertible Senior Notes	(7,592)	(9,474)
Intangible assets	(7,557)	(9,977)
Property, plant and equipment	(6,131)	(7,162)
Deferred Tax Liabilities, Gross	(21,280)	(26,613)
Total deferred tax liabilities	$ (58)	$ (1,970)

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Income Taxes Disclosure [Line Items]
Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions		$ 642	$ 773	$ 631
Deferred Tax Assets, Valuation Allowance	$ 3,087		7,774	3,087
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount			(4,700)
Unrecognized Tax Benefits	7,684	7,065	8,604	7,684	$ 7,065	$ 7,765
Deferred tax benefits	1,300		1,800	1,300
Federal Net Operating Loss carryforwards			8,300
State Net Operating Loss carryforwards			22,800
Federal alternative minimum tax credit			500
Gross research credits		765	979	722
Deferred Tax Liabilities, Undistributed Foreign Earnings			$ 500
Cumulative changes in ownership percentage			50.00%
Cumulative changes in ownership period			3 years
Realized upon settlement			50.00%
Unrecognized tax benefits that would impact effective tax rate	5,600		$ 6,400	5,600
Accrued interest and penalties associated with uncertain tax positions			200
Interest expense, net of accrued interest reversed		$ (200)	0	$ 100
Income tax reserves and related interest					$ 1,000
Federal research credits [Member]
Income Taxes Disclosure [Line Items]
Federal research credits			$ 3,700
Federal research credits, expiration date			Dec. 31, 2031
Gross State Research Credits [Member]
Income Taxes Disclosure [Line Items]
Gross research credits			$ 8,900
Effective Income Tax Rate Reconciliation, Tax Credit, Other, Amount			8,700
Effective Income Tax Rate Reconciliation, Tax Credit, Investment, Amount			$ 200
Federal [Member]
Income Taxes Disclosure [Line Items]
Gross research credits	$ 400

Income Taxes - Reconciliation o

Income Taxes - Reconciliation of Income Tax Computed at Federal Statutory Rate (Detail) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Tax benefit at statutory tax rate	$ (3,844)	$ (5,775)	$ (3,254)
State tax benefit, net of federal tax benefit	(151)	(390)	(235)
Permanent differences	70	129	157
Federal and state research credits—current year	(765)	(979)	(722)
Accrual (release) of uncertain tax positions	(21)	43	101
Expiration of statutes for uncertain tax positions	(953)	0	0
Impact of change in federal and state tax rate on revaluing deferred tax assets	110	(4)	56
Change in valuation allowance	2,331	4,687	756
Acquisition related adjustments	(485)	0	0
Other	(201)	(102)	(77)
Benefit for income taxes	$ (3,909)	$ (2,391)	$ (3,218)	$ (3,909)

Income Taxes - Summary of Unrec

Income Taxes - Summary of Unrecognized Tax Benefits (Detail) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2016	Dec. 31, 2015
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]
Beginning balance		$ 7,684	$ 7,065
Decreases related to prior year tax positions	$ (68)	(10)	(12)
Increases related to current year tax positions	642	773	631
Decreases due to settlements	(42)	0	0
Expiration of the statute of limitations for the assessment of taxes	(1,232)	0	0
Other	0	(157)	0
Ending balance	$ 7,065	$ 8,604	$ 7,684

Stockholders' Equity - Addition

Stockholders' Equity - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands	Apr. 23, 2013	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014	Mar. 02, 2015	Dec. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Deferred Bonus Liability		$ 500	$ 400	$ 700
Preferred stock, shares authorized		5,000,000	5,000,000	5,000,000
Preferred stock, shares outstanding			0	0
Weighted- average remaining contractual term, exercisable (in years)		3 years 11 months 11 days
Restricted stock granted (in shares)		185,000	171,000	145,000
Additional stock-based compensation expense				$ 300
Share-based compensation expense recognized		$ 7,986	$ 7,419	$ 6,724
Exercise price of stock (in dollars per share)		$ 17.49	$ 17.44	$ 16.37		$ 14.74
Available for future grant, (in shares)		2,572,000
Deferred period of grants (Condition 1)		1 year
Percentage of premium on amount deferred (Condition 1)		10.00%
Deferred period of grants (Condition 2)		2 years
Percentage of premium on amount deferred (Condition 2)		20.00%
Deferred period of grants (Condition 3)		4 years
Percentage of premium on amount deferred (Condition 3)		30.00%
Minimum percentage of common stock under payroll deductions		10.00%
Fair value of payroll deductions		85.00%
Share-based Compensation Arrangement by Share-based Payment Award, Purchase Period		6 years
Stock sold under the plan (in shares)		1,214,175
Capital shares reserved for future issuance (In shares)		285,825
Payments for repurchase of common stock		$ 20,168	$ 30,934	$ 1,956
Stock-based compensation expense		$ 20,168	$ 30,934	$ 1,956
Exercise of stock options		553,000	168,000	251,000
Shares reserved for purchase under ESPP (in shares)		285,825
Restricted stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted- average remaining contractual term, exercisable (in years)		10 years
Restricted stock granted (in shares)		200,000	200,000	100,000
Performance-based vesting period		4 years			3 years
Share-based compensation expense recognized		$ 2,400	$ 2,000	$ 2,100
Employee Deferred Bonus Compensation Program [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense recognized		$ 900	$ 700	$ 300
2010 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock reserve under equity incentive plans (in shares)		7,000,000
2010 Plan [Member] | Restricted stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Performance-based vesting period		1 year
Non-employee director [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Restricted stock granted (in shares)		400,000	500,000	400,000
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of deferred 2011 cash bonus		50.00%
Minimum [Member] | 2010 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price of stock (in dollars per share)		$ 8.50
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of deferred 2011 cash bonus		100.00%
Maximum [Member] | 2010 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price of stock (in dollars per share)		$ 27.91
Share Repurchase Program, Amendment [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Payments for repurchase of common stock	$ 50,000
Repurchase of available shares under share repurchase program (in shares)		1,152,386
Stock-based compensation expense		$ 19,600
Stock Repurchase Program, Remaining Authorized Repurchase Amount		$ 35,000

Stock-Based Compensation - Addi

Stock-Based Compensation - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands, shares in Millions	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense recognized	$ 7,986	$ 7,419	$ 6,724
Weighted-average grant date fair value of stock options granted (in dollars per share)	$ 6	$ 9.46	$ 10.96
Total intrinsic value for options exercised	$ 4,500	$ 1,600	$ 2,800
Total unrecognized compensation expense related to non-vested stock options	$ 5,800
Expected weighted-average period of recognition for unrecognized compensation expense	2 years 2 months
Maximum contractual term	10 years
Deferred Bonus Liability	$ 500	400	700
Deferred bonus compensation program [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense recognized	900	700	300
Recorded as a component of accrued payroll and related expenses	900	600	300
Restricted stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense recognized	$ 2,400	2,000	2,100
Expected weighted-average period of recognition for unrecognized compensation expense	2 years 5 months
Number of restricted share units issued (in shares)	0.1
Total unrecognized compensation expense related to non-vested stock awards	$ 3,100
Stock options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense recognized	$ 4,700	$ 4,700	$ 4,300

Stock-Based Compensation - Comp

Stock-Based Compensation - Compensation Expense Related to Stock-Based Compensation Plans (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	$ 7,986	$ 7,419	$ 6,724
Cost of sales [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	617	581	609
Research and development [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	1,551	734	1,062
Sales and marketing [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	1,189	1,554	1,059
General and administrative [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	$ 4,629	$ 4,550	$ 3,994

Stock-Based Compensation - Esti

Stock-Based Compensation - Estimated Fair Value of Each Stock Option Award (Detail)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Equity [Abstract]
Risk-free interest rate	1.47%	1.50%	1.59%
Expected option life (in years)	6 years 7 months 3 days	6 years 2 months 25 days	5 years 9 months 10 days
Volatility rate	36.00%	40.00%	42.00%
Dividend rate	0.00%	0.00%	0.00%

Stock-Based Compensation - Summ

Stock-Based Compensation - Summary of Status of Stock Option Activity (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Beginning balance, (in shares)	3,967	3,607	3,474
Granted, number of shares (in shares)	677	659	559
Exercised (in shares)	(553)	(168)	(251)
Cancelled (in shares)	(150)	(131)	(175)
Ending balance, (in shares)	3,941	3,967	3,607
Vested and expected to vest, (in shares)	3,781
Exercisable, (in shares)	2,529
Available for future grant, (in shares)	2,572
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Rollforward]
Beginning balance, weighted average exercise price per share (in dollars per share)	$ 17.44	$ 16.37	$ 14.74
Granted, weighted average exercise price per share (in dollars per share)	15.48	23.15	26.63
Exercised, weighted average exercise price per share (in dollars per share)	13.76	12.30	13.67
Cancelled, weighted average exercise price per share (in dollars per share)	20.86	23.41	20.63
Ending balance, weighted average exercise price per share (in dollars per share)	17.49	$ 17.44	$ 16.37
Vested and expected to vest, weighted average exercise price per share (in dollars per share)	17.45
Exercisable, weighted average exercise price per share (in dollars per share)	$ 15.92
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]
Weighted- average remaining contractual term, outstanding (in years)	5 years 6 months 6 days
Weighted- average remaining contractual term, vested and expected to vest (in years)	5 years 4 months 18 days
Weighted- average remaining contractual term, exercisable (in years)	3 years 11 months 11 days
Aggregate intrinsic value, outstanding	$ 19,236
Aggregate intrinsic value, vested and expected to vest	18,590
Aggregate intrinsic value, available for future grant	$ 15,451

Stock-Based Compensation - Su52

Stock-Based Compensation - Summary of Status of Stock Awards Activity (Detail) - $ / shares shares in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares [Roll Forward]
Beginning Balance (in shares)	459	402	454
Granted (in shares)	185	171	145
Vested (in shares)	(120)	(96)	(174)
Forfeited (in shares)	(23)	(18)	(23)
Ending Balance (in shares)	501	459	402
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Rollforward]
Beginning Balance, Weighted Average Grant Date Fair Value (in dollars per share)	$ 21.61	$ 14.84	$ 16.22
Granted, Weighted Average Grant Date Fair Value (in dollars per share)	16.14	22.79	25.73
Vested, Weighted Average Grant Date Fair Value (in dollars per share)	18.50	18.01	28.27
Forfeited, Weighted Average Grant Date Fair Value (in dollars per share)	20.80	22.87	18.19
Ending Balance, Weighted Average Grant Date Fair Value (in dollars per share)	$ 20.37	$ 21.61	$ 14.84

Commitments and Contingencies -

Commitments and Contingencies - Commitments for Minimum Rentals under Non-cancelable Leases (Detail) $ in Thousands	Dec. 31, 2016USD ($)
Commitments and Contingencies Disclosure [Abstract]
Operating Leases, 2017	$ 2,245
Operating Leases, 2018	2,296
Operating Leases, 2019	2,342
Operating Leases, 2020	2,365
Operating Leases, 2021	2,261
Operating Leases, Thereafter	625
Operating Leases, Minimum Payments, Total	12,134
Lease Obligation, 2017	937
Lease Obligation, 2018	946
Lease Obligation, 2019	956
Lease Obligation, 2020	967
Lease Obligation, 2021	0
Lease Obligation, Thereafter	0
Lease Obligation, Minimum Payments, Total	$ 3,806

Commitments and Contingencies54

Commitments and Contingencies - Additional Information (Detail) $ in Thousands	Mar. 18, 2016USD ($)	Dec. 31, 2014USD ($)ft²	Sep. 30, 2011USD ($)	Sep. 30, 2011USD ($)	Dec. 31, 2016USD ($)Lease	Dec. 31, 2015USD ($)	Dec. 31, 2014USD ($)ft²	Apr. 01, 2011USD ($)
Sale Leaseback Transaction [Line Items]
Change in amount of contingent consideration, liability	$ 400				$ 353
Rent expense under operating leases		$ 3,300			$ 2,200	$ 2,300
Lease expiration year					2,022
Number of extension | Lease					2
Extend the lease options					5 years
Lease incentives for tenant improvements					$ 1,700
Facility sold					15,000
Capital contributed					3,800
Cash transaction, netting					$ 7,000
Partnership that acquired the facility					25.00%
Lease payments		$ 1,100			$ 900	1,100	$ 1,100
Purchase Commitment, Remaining Minimum Amount Committed					4,300
Accrued in other current liabilities					4,999	6,999
Agreement for payments totaling								$ 29,500
Initial cash payments			$ 13,800
Fixed cash payment			$ 15,700
Contract value Discount				$ 1,000
One-time charge to cost of sales					700
Amortization expense					9,500	10,200	17,400
Company had royalty and license expenses relating to those agreements					$ 800	500	$ 900
San Diego [Member]
Sale Leaseback Transaction [Line Items]
Lease term period					Dec. 1, 2019
Number of extension | Lease					3
Extend the lease options					5 years
Amended terms					10 years
Property Subject to Operating Lease [Member]
Sale Leaseback Transaction [Line Items]
Area under new operating lease | ft²		30,000					30,000
Patented technology [Member]
Sale Leaseback Transaction [Line Items]
Assigned licensed technology					$ 28,800
License agreements [Member]
Sale Leaseback Transaction [Line Items]
Amortization expense		$ 8,000				700	$ 8,000
Research and Development Collaboration Agreements [Member]
Sale Leaseback Transaction [Line Items]
Current commitments					2,300
Claims and litigation [Member]
Sale Leaseback Transaction [Line Items]
Accrued in other current liabilities						200
Research and Development Arrangement [Member]
Sale Leaseback Transaction [Line Items]
Milestone Payments Made Under Agreement					900	1,700
Bio Helix [Member]
Sale Leaseback Transaction [Line Items]
Payments for Royalties					200	100
Change in amount of contingent consideration, liability					$ 600	$ 21	$ 800

Commitments and Contingencies C

Commitments and Contingencies Contingent Consideration (Acquisitions) (Details) $ in Thousands, € in Millions	Mar. 18, 2016USD ($)	Dec. 31, 2016USD ($)	Dec. 31, 2016USD ($)	Dec. 31, 2015USD ($)	Dec. 31, 2014USD ($)	Dec. 31, 2016EUR (€)	Aug. 31, 2013USD ($)	Aug. 31, 2013EUR (€)	May 31, 2013USD ($)
Business Acquisition, Contingent Consideration [Line Items]
Change in amount of contingent consideration, liability	$ 400		$ 353
Current portion of contingent consideration		$ 2,826	2,826	$ 1,286
Contingent consideration non-current portion		2,349	2,349	4,230
Andiatec Acquisition [Member]
Business Acquisition, Contingent Consideration [Line Items]
Contingent consideration non-current portion		100	100
Bio Helix [Member]
Business Acquisition, Contingent Consideration [Line Items]
Change in amount of contingent consideration, liability			600	21	$ 800
Payments for Royalties			200	100
Contingent consideration									$ 10,000
Current portion of contingent consideration		2,700	2,700
Contingent consideration non-current portion				1,900
Maximum [Member] | Andiatec Acquisition [Member]
Business Acquisition, Contingent Consideration [Line Items]
Contingent consideration							$ 500	€ 0.5
Minimum [Member] | Bio Helix [Member]
Business Acquisition, Contingent Consideration [Line Items]
Contingent consideration									$ 5,000
Research and Development Arrangement [Member]
Business Acquisition, Contingent Consideration [Line Items]
Milestone Payments Made Under Agreement			900	1,700
Research and Development Arrangement [Member] | Andiatec Acquisition [Member]
Business Acquisition, Contingent Consideration [Line Items]
Contingent consideration		3,100	3,100			€ 3
Fair Value, Inputs, Level 3 [Member]
Business Acquisition, Contingent Consideration [Line Items]
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings		$ 100	$ 485	$ 100	$ 900

Industry and Geographic Infor56

Industry and Geographic Information - Additional Information (Detail) $ in Millions	12 Months Ended
	Dec. 31, 2016USD ($)Segment	Dec. 31, 2015USD ($)	Dec. 31, 2014
Revenue, Major Customer [Line Items]
Number of reportable segments | Segment	1
Customer Concentration Risk [Member] | Non-U.S. Customers [Member]
Revenue, Major Customer [Line Items]
Accounts receivable	$ 6.8	$ 5.6
Customer Concentration Risk [Member] | Sales [Member]
Revenue, Major Customer [Line Items]
Percentage of risk concentration by major customer	44.00%	48.00%	48.00%
Customer Concentration Risk [Member] | Sales [Member] | Non-U.S. Customers [Member]
Revenue, Major Customer [Line Items]
Percentage of risk concentration by major customer	17.00%	14.00%	13.00%
Credit Concentration Risk [Member]
Revenue, Major Customer [Line Items]
Accounts receivable	$ 13.9	$ 12
Credit Concentration Risk [Member] | Accounts Receivable [Member] | Minimum [Member]
Revenue, Major Customer [Line Items]
Percentage of risk concentration by major customer	10.00%	10.00%

Industry and Geographic Infor57

Industry and Geographic Information - Sales to Individual Customers in Excess of 10% of Total Revenue (Detail) - Sales [Member] - Customer Concentration Risk [Member]	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Revenue, Major Customer [Line Items]
Sales percentage	44.00%	48.00%	48.00%
Customer A [Member]
Revenue, Major Customer [Line Items]
Sales percentage	16.00%	20.00%	19.00%
Customer B [Member]
Revenue, Major Customer [Line Items]
Sales percentage	15.00%	17.00%	18.00%
Customer C [Member]
Revenue, Major Customer [Line Items]
Sales percentage	13.00%	11.00%	11.00%

Industry and Geographic Infor58

Industry and Geographic Information - Long-lived Assets (Excluding Intangible Assets) and Total Net Revenue (Detail) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-lived assets, Total	$ 50,858				$ 52,547				$ 50,858	$ 52,547
Total revenues	52,808	$ 49,341	$ 39,133	$ 50,321	52,412	$ 46,812	$ 35,204	$ 61,701	191,603	196,129	$ 184,158
Federal [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-lived assets, Total	50,774				52,426				50,774	52,426
Total revenues									158,244	168,809	159,845
Foreign [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-lived assets, Total	$ 84				$ 121				84	121
Total revenues									$ 33,359	$ 27,320	$ 24,313

Industry and Geographic Infor59

Industry and Geographic Information - Consolidated Net Product Revenues by Disease State (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Segment Reporting Information [Line Items]
Revenues	$ 191,603	$ 196,129	$ 184,158
Infectious Disease [Member]
Segment Reporting Information [Line Items]
Revenues	121,416	130,348	118,715
Women's Health [Member]
Segment Reporting Information [Line Items]
Revenues	9,506	5,424	3,418
Gastrointestinal Disease [Member]
Segment Reporting Information [Line Items]
Revenues	40,083	43,747	44,771
Royalty, License Fees and Grant Revenue [Member]
Segment Reporting Information [Line Items]
Revenues	9,387	9,001	7,779
Other Disease [Member]
Segment Reporting Information [Line Items]
Revenues	$ 11,211	$ 7,609	$ 9,475

Fair Value Measurement - Assets

Fair Value Measurement - Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Assets:
Total assets measured at fair value	$ 133,540
Liabilities:
Total liabilities measured at fair value	5,175	$ 5,516
Cash equivalents [Member]
Assets:
Total assets measured at fair value	133,540	133,147
Contingent consideration [Member]
Liabilities:
Total liabilities measured at fair value		5,516
Level 1 [Member]
Assets:
Total assets measured at fair value		133,147
Liabilities:
Total liabilities measured at fair value	0	0
Level 1 [Member] | Cash equivalents [Member]
Assets:
Total assets measured at fair value	133,540	133,147
Level 1 [Member] | Contingent consideration [Member]
Liabilities:
Total liabilities measured at fair value	0	0
Level 2 [Member]
Assets:
Total assets measured at fair value	0	0
Liabilities:
Total liabilities measured at fair value	0	0
Level 2 [Member] | Cash equivalents [Member]
Assets:
Total assets measured at fair value	0	0
Level 2 [Member] | Contingent consideration [Member]
Liabilities:
Total liabilities measured at fair value	0	0
Level 3 [Member]
Assets:
Total assets measured at fair value	0	0
Liabilities:
Total liabilities measured at fair value	5,175	5,516
Level 3 [Member] | Cash equivalents [Member]
Assets:
Total assets measured at fair value	0	0
Level 3 [Member] | Contingent consideration [Member]
Liabilities:
Total liabilities measured at fair value	$ 5,175	$ 5,516

Fair Value Measurement - Additi

Fair Value Measurement - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total assets measured at fair value	$ 133,540	$ 133,540
Total liabilities measured at fair value	5,175	5,175	$ 5,516
Cash equivalents [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total assets measured at fair value	133,540	133,540	133,147
Contingent consideration [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total liabilities measured at fair value			5,516
Level 1 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total assets measured at fair value			133,147
Total liabilities measured at fair value	0	0	0
Level 1 [Member] | Cash equivalents [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total assets measured at fair value	133,540	133,540	133,147
Level 1 [Member] | Contingent consideration [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total liabilities measured at fair value	0	0	0
Level 2 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total assets measured at fair value	0	0	0
Total liabilities measured at fair value	0	0	0
Level 2 [Member] | Cash equivalents [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total assets measured at fair value	0	0	0
Level 2 [Member] | Contingent consideration [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total liabilities measured at fair value	0	0	0
Level 3 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings	100	485	100	$ 900
Total assets measured at fair value	0	0	0
Total liabilities measured at fair value	5,175	5,175	5,516
Level 3 [Member] | Cash equivalents [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total assets measured at fair value	0	0	0
Level 3 [Member] | Contingent consideration [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total liabilities measured at fair value	$ 5,175	$ 5,175	$ 5,516

Fair Value Measurement - Change

Fair Value Measurement - Changes in Estimated Fair Value of Contingent Consideration Liabilities (Detail) - USD ($) $ in Thousands	Mar. 18, 2016	Dec. 31, 2016	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Change in amount of contingent consideration, liability	$ 400		$ 353
Level 3 [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Balance			5,516
Cash payments			(207)
Net gain recorded for fair value adjustments		$ (100)	(485)	$ (100)	$ (900)
Unrealized gain on foreign currency translation			(2)
Balance				$ 5,516
Contingent consideration [Member] | Level 3 [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Balance		$ 5,175	$ 5,175

Employee Benefit Plan - Additio

Employee Benefit Plan - Additional Information (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Compensation Related Costs [Abstract]
Pay contributed by employer	50.00%
Pay contributed by employee	6.00%
Contribution to 401 (K) Plan	$ 1.5	$ 1.3	$ 1.1

Impairment Loss (Details)

Impairment Loss (Details) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Sep. 30, 2014	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Property, Plant and Equipment [Line Items]
Impairment loss		$ 0	$ 0	$ 3,558
Loss on contract termination	$ 200
Software and Software Development Costs [Member]
Property, Plant and Equipment [Line Items]
Impairment loss	1,500
In Process Research and Development [Member]
Property, Plant and Equipment [Line Items]
Impairment loss	1,600	$ 0
Other Intangible Assets [Member]
Property, Plant and Equipment [Line Items]
Impairment loss	300
Project Stella [Member]
Property, Plant and Equipment [Line Items]
Impairment loss	$ 3,400

Acquisitions - Additional Infor

Acquisitions - Additional Information (Detail) - USD ($) $ in Thousands	Mar. 18, 2016	Dec. 31, 2016
Business Combinations [Abstract]
Cash consideration	$ 5,500
Other payments to acquire businesses	5,100
Change in amount of contingent consideration, liability	$ 400	$ 353

Selected Quarterly Financial 66

Selected Quarterly Financial Data (unaudited) - Quarterly Financial Data (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Income Statement [Abstract]
Total revenues	$ 52,808	$ 49,341	$ 39,133	$ 50,321	$ 52,412	$ 46,812	$ 35,204	$ 61,701	$ 191,603	$ 196,129	$ 184,158
Cost of sales (excludes amortization of intangible assets)	19,119	17,728	17,318	19,249	18,122	16,961	15,493	21,112	73,414	71,688	74,180
Gross profit	32,001	30,023	20,225	29,482	32,700	28,261	18,121	39,018
Total costs and expenses	46,893	47,216	48,152	53,781	49,750	45,600	45,029	53,012	196,042	193,391	193,366
Net income (loss)	$ (1,950)	$ (572)	$ (7,840)	$ (3,446)	$ (377)	$ (762)	$ (8,931)	$ 3,991	$ (13,808)	$ (6,079)	$ (7,074)
Basic and diluted loss per share	$ (0.06)	$ (0.02)	$ (0.24)	$ (0.11)	$ (0.01)	$ (0.02)	$ (0.26)	$ 0.12
Diluted net earnings (loss) per share					$ (0.01)	$ (0.02)	$ (0.26)	$ 0.11

Selected Quarterly Financial 67

Selected Quarterly Financial Data (unaudited) - Quarterly Financial Data (Footnote) (Detail) - USD ($) $ in Millions	3 Months Ended
	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015
Income Statement [Abstract]
Amortization of intangible assets included in gross profit	$ 1.7	$ 1.6	$ 1.6	$ 1.6	$ 1.5	$ 1.6	$ 1.6	$ 1.6

Consolidated Valuation and Qu68

Consolidated Valuation and Qualifying Accounts (Detail) - Allowance for Doubtful Accounts [Member] - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Movement in Valuation Allowances and Reserves [Roll Forward]
Beginning Balance	$ 7,488	$ 8,221	$ 5,790
Additions charged to expense or as reductions to revenue	28,329	31,532	23,447
Deductions	(28,652)	(32,265)	(21,016)
Ending Balance	$ 7,165	$ 7,488	$ 8,221